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Squamous-cell carcinoma of the oesophagus is a formidable disease which poses a 
significant health risk in developing countries where incidence is high and survival is low. 
Investigating the poorly understood mechanisms involved in oesophageal tumourigenesis 
may provide a platform to develop improved diagnostic techniques and therapies. The 
growth hormone (GH) signalling axis is important for proper cellular and organ system 
function. The axis has been shown to play a role in a number of cancers. Additionally, GH has 
shown to induce neoplasms in vivo while forced autocrine signalling of GH was shown to 
promote carcinogenesis in several in vitro models, highlighting the role of GH in 
tumourigenesis. Several studies showed that the tumourigenic effects of GH are largely 
mediated by its receptor, growth hormone receptor (GHR). The aim of this project is to 
therefore identify the role GHR in oesophageal squamous-cell carcinoma (OSCC) using an in 
vitro model. mRNA analysis showed expression of endogenous GH mRNA in a majority of 
OSCC cell lines tested, while nearly all expressed some form of GHR. Few, however, 
expressed mRNA for the more-active isoform of GHR, d3GHR, indicating GH may play a role 
in OSCC, and may be mediated by full-length GHR (flGHR) in a majority of cell lines. Western 
blotting for GHR remained largely unsuccessful, indicative of the short half-life of mature 
GHR and the possible insensitivity of commercially-available GHR antibodies. However, 
unglycosylated, immature GHR is likely detected as a 95kDa band, while mature GHR may be 
detected as a 120kDa band. However, a non-specific 95kDa band was also detected, thereby 
interfering with detection of true levels of premature GHR in OSCC cell lines. GHR 
knockdown by small interfering RNA indicated that the GH axis may play a role in 
proliferation in a subset of patients that is mediated by GHR, but does not affect responses 
to the chemotherapeutic agents doxorubicin and cisplatin. Additionally, the mRNA 
expression of GHR did not correlate with the expression of functional GHR protein in a 
number of OSCC cell lines. These results together indicate while GHR may play a role in a 
subset of patients, the role is limited to proliferation when only investigating the effects of 
GH on proliferation and chemoresistance. However, investigating additional markers of 
tumourigenesis is needed to further elucidate the role of GH/GHR signalling in OSCC. 
Additionally, the potential tumourigenic effects of GH mediated by prolactin receptor (PRLR) 


















In a report published in 2011 by the Centre for Disease Control, it was reported that cancer 
ranked as the second leading cause of death worldwide (Heron, 2011). Based on estimates, 
there were approximately 12.7 million newly-diagnosed cancer cases and 7.6 million cancer-
related deaths in 2008 (Ferlay et al., 2010). These figures are anticipated to continue 
increasing due to the aging and growth of the world’s population, with the incidence of 
cancer in the United States of America anticipated to increase 45% from the years 2010 to 
2030 alone (Smith et al., 2009). Incidence rates in developed countries are double those 
seen in developing countries due to the adoption of a lifestyle more suited to the 
development of cancer, such as physical inactivity, smoking, and diets rich in fat (Jemal et al., 
2011). However, cancer mortality rates in developed and developing countries remain 
similar, with cancer survival being poorer in developing countries. This can be attributed to a 
combination of late-stage diagnoses, limited access to health care, and inadequately funded 
government health care budgets (Jemal et al., 2011). Cancer therefore poses an increasing 
threat to health and economic systems, particularly in developing countries. This paints a 
bleak picture for the economically developing world, and highlights the need for cancer 
research within these countries. There is therefore a need to increase resources for cancer 
research, comparable to the levels of funding dedicated to other diseases known to play 

















1.2 The Hallmarks of Cancer 
Cancer, by popular definition, is the unregulated proliferation of a population of cells. 
However, this simple definition does not suffice. The ever-increasing insight of the molecular 
mechanisms of cancer, generated by research, have shown that cancer is in fact a 
multifactoral disease, which ultimately manifests as uncontrolled and rapid proliferation of 
cells into the formation of a tumour. Yet, this would not occur unless cells developed certain 
characteristics to allow such unregulated growth. Hanahan and Weinberg (Hanahan and 
Weinberg, 2011) detailed six characteristics that normal cells would have to acquire before 
becoming cancerous. They also suggested that these characteristics are facilitated by the 
genomic instability present within pre-malignant cells that allows mutations to occur and 
thus the acquisition of such characteristics. The six hallmarks of cancer are as follows: 
sustenance of proliferative signalling, evasion of growth suppressors, resistance of cell 
death, enabling replicative immortality, induction of angiogenesis, and activation of invasion 
and metastasis, with sustenance of proliferative signalling being arguably the most 
fundamental trait. The process whereby these hallmarks are acquired relies heavily on the 
manipulation of existing intracellular signalling pathways brought about directly through 
genetic instability. 
1.3Oesophageal Cancer 
Given the threat posed by cancer to developing regions, oesophageal cancer is of significant 
concern. Oesophageal cancer is the eighth most common cancer and is the sixth leading 
cause of cancer death worldwide (Parkin et al., 1999). In 2011, an estimated 481 205 new 
cases of oesophageal cancer were diagnosed with 406 800 deaths attributed to the disease 
(Jemal et al., 2011), making it one of the highest mortality rates compared to other cancers. 
Significantly, it is estimated that 83% of new diagnoses, and 85% of deaths attributed to 
oesophageal cancer occurred in developing countries (Fig.1), with males being two times 













Figure 1: Worldwide cancer incidence and mortality rates (Ferlay et al., 2010).(A) Estimated incidence and mortality cases 
(thousands) in developing and developed regions for (A) men, and(B)women. 
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There are two subtypes of oesophageal cancer, namely squamous-cell carcinoma (SCC) and 
adenocarcinoma (AC) (Daly et al., 2000), however, on rare occasions other carcinomas, 
melanomas, carcinoids, and lymphomas may also develop in the oesophagus (Enzinger and 
Mayer, 2003). Both subtypes share a common lineage, in that both arise from epithelial cells 
in the oesophagus. Yet, the two subtypes are distinct in that SCC originates from squamous 
cells in the epithelial layer, while AC arises from glandular cells present in the epithelium of 
the oesophagus. Furthermore, SCC mainly occurs in the proximal and middle oesophagus 
while AC occurs mainly in the distal oesophagus at the gastro-oesophageal junction (Daly et 
al., 2000; Siewert et al., 2001). 
Geographically, oesophageal cancer is present worldwide, however, incidence rates vary 
greatly internationally with the higher rates found in developing countries (Fig.1). The 
highest incidence rates are found in Southern Africa (Fig.2) (Jemal et al., 2011). 
 
Figure 2: Age standardised incidence of oesophageal cancer by region (Jemal et al., 2011). Incidence rates are indicated 














Incidence of the two subtypes of oesophageal cancer varies internationally, with SCC 
occurring predominantly in developing regions, and AC being most common in developed 
regions. The heterogeneity of oesophageal cancer is further reflected in the different risk 
factors attributed to each subtype. Any factor that causes continuous irritation and 
inflammation of the oesophageal mucosa appears to increase the incidence of SCC. It is 
therefore unsurprising that tobacco smoking, alcohol consumption, and infection by human 
papilloma virus are possible risk factors attributed to the development of SSC (Enzinger and 
Mayer, 2003; Hendricks and Parker, 2002).As with SCC, there are several risk factors 
attributed to the development of AC, chief amongst these are Barrett’s oesophagus, acid 
reflux, and obesity (Enzinger and Mayer, 2003; Hendricks and Parker, 2002). 
Interestingly, there appears to be a genetic predisposition to developing SCC with, in a small 
number of cases, familial clusters being diagnosed in families with a history of 
nonepidermoytic palmoplantar keratoderma, a rare autosomal d minant disorder defined 
by a genetic abnormality at chromosome 17q25 that results in the thickening of the 
oesophageal mucosa (Enzinger and Mayer, 2003; Risk et al., 1999). Regardless of the rarity 
of such cases, these rare familial conditions offer insights into the mechanistic processes 
underlying the development of sporadic cases. Additionally, few modifications to molecular 
mechanisms have been described in SSC. For one, the cell cycle regulator, Cyclin D1, has 
been shown to be overexpressed in SSC, and its expression is shown to correlate to lymph 
node metastasis and survival (Nagasawa et al., 2001; Sarbia et al., 1999). Also, another cell 
cycle regulator, p53, has been shown to be overexpressed in half of South African patients 
with SSC (Chetty and Simelane, 1999). However, despite such insight into the aetiology of 
oesophageal cancer, specifically SSC, the molecular mechanisms behind its pathogenesis 

















The five-year survival rate of oesophageal cancer varies according to its stage when 
detected. The five-year survival rate when detected at stage 0 (a stage where abnormal cells 
carry a high grade of dysplasia but are not yet malignant) it is approximately 95% (Enzinger 
and Mayer, 2003). This drastically drops to 10%-40% when detected at stage II (abnormal 
cells have become malignant and have invaded the oesophageal wall), and by stage IV (distal 
metastasis has occurred), less than 1% of patients survive for five years (Enzinger and Mayer, 
2003). Despite such low survival numbers, the five-year survival rate of oesophageal cancer 
is not drastically different from other cancers. However, the poor prognosis and high 
mortality rate when compared to other cancers may be attributed to its asymptomatic 
development and thus late detection (Hendricks and Parker, 2002). Therefore, in many cases 
oesophageal cancer is diagnosed in its late stages resulting in a low survival rate of patients 
and therefore its remarkably high mortality rate. 
The poor prognosis of oesophageal cancer patients may also be attributed to its ineffective 
treatment currently being employed. Both SCC and AC initially are responsive to 
chemotherapy, with significant shrinkage of the tumours occurring in a majority of patients 
(Enzinger and Mayer, 2003). However, this response to chemotherapy typically lasts no 
longer than a few months, with responses to chemotherapy rarely exceeding one year 
(Enzinger and Mayer, 2003). This could be attributed to the presence of chemoresistant 
cancer stem cells present in oesophageal cancer tumours as previously demonstrated in 
patient tumours (Li et al., 2011), and oesophageal cancer cell lines (Chen et al., 2012). 
Surgery remains the most effective way of treating early-stage oesophageal cancer, but with 
its asymptomatic development and thus late detection, surgery is often ineffective (Enzinger 
and Mayer, 2003). Its ineffective treatment, along with its asymptomatic development, late 
detection, and poor understanding of the molecular mechanisms of its pathogenesis gives 
oesophageal cancer its distinctly poor prognosis and remarkably high mortality rate when 
compared to other cancers. There is therefore a need to elucidate its molecular mechanisms 
in order to allow for earlier detection and/or more efficient treatment of oesophageal 
cancer. The value of elucidating the molecular process critical for the survival of oesophageal 
cancer is best illustrated by the development of a drug like Herceptin®. The drug targets and 
facilitates the destruction of breast cancer cells that overexpress Her2/Neu, a member of the 












proteins and pathways in oesophageal cancer will facilitate the development of better 
therapeutics. 
1.4 The GH/IGF1 Axis 
One of the signalling axes well documented to be altered in various cancers is that of the 
growth hormone/insulin-like growth factor 1 (GH/IGF1) axis. It is well established that, 
normally, GH is extremely important for the regulation of postnatal growth and 
metabolism(Harvey, 2010). GH has also shown to play a role in amino acid transportation, 
mitogenesis, prevention of apoptosis, and differentiation and reorganisation of cytoskeletal 
architecture, indicating the highly pleiotropic effects of GH (Eisenhauer et al., 1995; Goh et 
al., 1997; Zhu et al., 2001).  Additionally, GH plays a role in ensuring the proper function of 
several physiological systems such as the cardiovascular, reproductive, gastrointestinal, and 
renal systems. Its primary role, the regulation of postnatal growth, is largely mediated 
through the potent mitogen, IGF1 (Chhabra et al., 2011). Normally, GH is secreted by the 
pituitary gland into the blood stream where it is free to bind to its ubiquitously expressed 
receptor, growth hormone receptor (GHR).  
The biosynthesis and secretion of GH is tightly regulated by several hormones secreted 
primarily by the hypothalamus (Fig.3). Ghrelin is a hormone secreted by the stomach just 
before meals (Cummings et al., 2002; Date et al., 2000; Kojima et al., 1999). Once secreted, 
ghrelin binds to its receptor present on somatotroph cells in the pituitary and induces the 
biosynthesis and secretion of GH by these cells (Kojima et al., 1999)(Fig.3). Similarly, growth 
hormone-releasing hormone (GHRH) is secreted by the hypothalamus and binds to its 
receptor expressed on somatotroph cells which also induces the synthesis and secretion of 
GH into the blood stream (Garcia-Fernandez et al., 2003; Lin-Su and Wajnrajch, 2002)(Fig.3). 
The synthesis of GH is directly inhibited by the hypothalamic production of somatostatin, 













Figure 3: The IGF1/GH axis (Holt, 2002). GH secreted by the pituitary, under the regulation of GHRH, ghrelin, and 
somatostatin, is free to either bind to GHBP or to its receptor expressed on target cells. Binding to its receptor, particularly 
on liver cells, results in the biosynthesis and secretion of IGF1, which is then free to bind to its receptor on target tissues or 
to IGFBP and ALS. In cells other than those of the liver, binding of GH to GHR may also induce autocrine and endocrine 
signalling of IGF1. 
 
Once secreted into the bloodstream, GH may either bind to its receptor, growth hormone 
receptor (GHR), present on target tissues or bind to growth hormone-binding protein (GHBP) 
(Fig.3). Binding of GH to GHBP limits the available amount of free GH able to bind to its 
receptor thereby creating a GH reservoir (Baumann et al., 1988). It also protects GH from 
degradation (Baumann et al., 1987; Clark et al., 1991), and increases the hormone’s short 
half-life in serum (Clark et al., 1991). If bound to its receptor, several intracellular signalling 
pathways are activated. These pathways converge and activate several transcription factors, 
the most notable being the signal transducer and activator of transcription (STAT) 












Activation of STAT transcription factors by GH induces transcription and secretion of IGF1 
(Davey et al., 1999) (Fig.3). In addition to GHR, GH may bind to the prolactin receptor (PRLR) 
since both GHR and PRLR are similar in structure and function (Somers et al., 1994). GHR is 
ubiquitously expressed, but is more abundant in the liver (Frank and Messina, 2002). It is 
therefore unsurprising that the liver is the main origin for IGF1 synthesis and secretion 
(Fig.3). Once secreted by the liver, IGF1 may either act on target tissue to exert its mitogenic 
effects in an endocrine manner, or bind to the IGF-binding protein (IGFBP) and acid labile 
subunit (ALS) complex, preventing it from binding to its receptor, thus negatively regulating 
IGF1 downstream effects (Fig.3) (Scott et al., 1994). However, autocrine/paracrine signalling 
of IGF1 by GH binding to target tissues other than the liver cannot be excluded (Fig.3). Once 
secreted, IGF1 also negatively regulates GH synthesis and secretion by inhibiting GHRH. 
1.5 Growth Hormone Receptor 
The effects of GH on postnatal growth and metabolism, and on several organ systems are 
mediated through its receptor, GHR. GHR is a single membrane-spanning type I glycoprotein 
member of the cytokine receptor superfamily (Bazan, 1990; Brooks et al., 2008; Frank and 
Messina, 2002). The type I cytokine receptor family includes many other receptors, however, 
GHR was the first identified member of this superfamily (Cosman et al., 1990). 
1.5.1 GHR Gene Structure 
The gene encoding GHR is present on chromosome 5 at position p13-p12 and spans roughly 
90kb (Godowski et al., 1989).It includes 9 exons, exons 2 to 10 (Fig.4). Exon 2 encodes some 
of the 5’ untranslated region (UTR), and the signal sequence (Frank and Messina, 2002) 
(Fig.4). The signal sequence encodes for a signal peptide that is present on all proteins 
designated for the secretory pathway which are either secreted from the cell, or inserted in 
cellular membranes (Blobel and Dobberstein, 1975). Exons 3 to 7 encode the majority of the 
extracellular domain of the protein(Frank and Messina, 2002) (Fig.4). Exon 8 encodes the 24-
residue transmembrane region and a few residues of the extra- and intracellular domain 
sides flanking it (Frank and Messina, 2002) (Fig.4). Exons 9 and 10 encode for the remainder 














Figure 4: Schematic of the GHR gene (Lau et al., 2007). Exons are numbered and are indicated as boxes. Intron sizes 
between exons are also indicated. 
 
The gene is highly conserved, although, splicing of the gene varies between species. For 
instance, in the mouse, the gene is spliced to generate the transcript encoding GHBP (Edens 
et al., 1994). Furthermore, several human isoforms of GHR exist, arising from gene splicing, 
each with differing functions and ligand affinity. These isoforms will be explained in detail 
later. It was found that human transcripts of the gene often contained variations within the 
5’UTR (Pekhletsky et al., 1992). Exons encoding the 5’UTR have been seen to be alternatively 
spliced to give rise to these 5’UTR variants (Pekhletsky et al., 1992). Additionally, 5’UTR 
splice variants appear to be tissue specific, indicating a possible complex tissue-specific 
regulatory role of the 5’UTR affecting the translational efficiency of the mRNAs (Edens and 





















1.5.2 GHR Protein Structure 
As stated before, GHR is a glycoprotein of the type I cytokine receptor family (Bazan, 1990; 
Brooks et al., 2008; Frank and Messina, 2002). Its cDNA is predicted to encode a protein 
approximately 70kDa in size and 620 amino-acids long (Leung et al., 1987). However, it is 
commonly seen to migrate as a 120-130kDa band in reducing SDS-polyacrylamide gels when 
expressed in mammalian cells, due to post-translational modifications such as glycosylation 
and ubiquitination (Asa et al., 2007; Kerkhof et al., 2007; Stubbart et al., 1991; Wang et al., 
1992). Characteristic features of the type I cytokine family of proteins include; (i) possession 
of a single membrane spanning domain, (ii) conserved cysteine residues in the extracellular 
domain, (iii) a conserved WSXWS-like motif, (iv) two conserved proline-rich domains termed 
Box 1 and Box 2, and (v) lack of intrinsic kinase activity. 
 
 
Figure 5: Schematic of GHR protein undimerised monomer (Zhu et al., 2001).Extracellular, transmembrane, and 
intracellular domains are indicated. Cysteine residues and the WSXWS motif present in subdomain 1 and 2 are also 













The extracellular domain consists of two fibronectin type III β sandwich domains comprising 
Subdomain 1 and 2 and is predicted to extend from residues 1-246 (Fig.5) (Brooks et al., 
2008; Frank and Messina, 2002; Zhu et al., 2001). The two subdomains are connected by a 
four residue hinge region(Fig.5)(Brooks et al., 2008; Frank and Messina, 2002; Zhu et al., 
2001). Four conserved cysteine residues are present in Subdomain 1, which form two pairs 
that engage in forming disulphide linkages (Fig.5) (Frank and Messina, 2002; Zhu et al., 
2001). Additionally, the WSXWS-like motif is present in Subdomain 2 (Fig.5) (Frank and 
Messina, 2002; Zhu et al., 2001). Studies have indicated that the conserved cysteine residues 
along with the WSXWS-like motif are both critical for the structural integrity of the 
receptor’s extracellular domain while not being involved in GH binding (Fuh et al., 1990).  
 
Unlike the extracellular domain of GHR, there is no structural data for the intracellular 
domain (Yang et al., 2007). The intracellular domain contains the two conserved proline-rich 
boxes and is roughly 350 residues long (Fig.5) (Frank and Messina, 2002). Box 1 is critical for 
the direct association of Janus tyrosine kinase 2 (JAK2) with GHR and for most other GH-
stimulated intracellular functions (Brooks et al., 2008; Frank and Messina, 2002; Zhu et al., 
2001). The role of Box 2 is less well defined. In addition to being rich in proline residues, Box 
2 contains a short stretch of acidic residues likely to be required for optimal JAK2 interaction 
to Box 1, but unlike Box 1, does not serve as a direct binding site for JAK2 (Frank et al., 1994). 
Several tyrosine residues that serve as substrates for phosphorylation by JAK2 are also 
present in the intracellular domain of the receptor (Fig.5) (Brooks et al., 2008; Frank and 
Messina, 2002). A phenylalanine residue at position 327 has been shown to be important for 
GH-induced receptor internalisation and degradation (Allevato et al., 1995). Additionally, a 
conserved ubiquitin-dependent endocytosis (UbE) motif is in close proximity to the  
phenylalanine, and is thought to be important in mediating GH-induced receptor 



















1.5.3 GHR Activation and Signalling 
 
Two models of GHR activation by GH have been proposed. It was initially accepted that GHR 
exists  as a monomer on the cellular surface, and that GH induces homodimerisation of these 
receptors (Fig.6A) (Cunningham et al., 1991). However, recent evidence suggest that GHR 
may already exist as pre-formed homodimers on the cell surface prior to GH binding (Fig.6B) 
(Brown et al., 2005; Gent et al., 2002). 
 
 
Figure 6: Activation of GHR by GH (Kaabi, 2012). (A) Ligand-dependant dimerisation model. Binding of GHR to site 1 of GH 
allows binding of a second GHR monomer to site 2 of GH, thus forming homodimers. The required formation of GHR dimers 
results in downstream activation of the receptors. (B) Ligand-independent dimerisation model. Binding of GH to pre-formed 






















GH possesses two binding sites; a high affinity site 1, and a lower affinity site 2 (Fig.6) (Fuh et 
al., 1992). The ligand-dependant model of GHR homodimerisation predicts that the higher 
affinity site 1 of GH interacts with the first receptor, which then allows for the interaction of 
the lower affinity site 2 to interact with a second receptor (Fig.6A) (Cunningham et al., 1991; 
Frank and Messina, 2002; Fuh et al., 1992). The resulting dimerisation provides the signal to 
generate the appropriate activation of receptor signalling (Fuh et al., 1992). Several lines of 
evidence exist that support this model; (i) self-antagonism of GHR activation by GH at high 
concentrations, since all available GHR monomers are bound to GH via the high affinity site 
1, leaving few available GHR for site 2 binding and dimerisation (Fuh et al., 1992), (ii) 
disruption of interaction between site 2 and receptor by means of point mutation of site 2 
produces antagonistic effects (Fuh et al., 1992), (iii) naturally occurring short isoforms of 
GHR lacking intracellular domains are shown to inhibit the function of full-length GHR 
presumably by forming non-functioning homodimers (Ross et al., 1997). In retrospect, the 
last two lines of evidence may serve as evidence for the ligand-independent dimerisation 
model, but at the time, was considered evidence for th  ligand-dependent dimerisation 
model. 
 
However, recent evidence contradicts the long-held ligand-dependant dimerisation model 
suggesting that GHR already exists as homodimers irrespective of GH association with the 
receptor. In this model, GH binds to an already formed homodimer of the receptor, resulting 
in a conformational change of the intracellular domain of the receptor, that in turn initiates 
associated tyrosine kinases and signal transduction (Fig 6B) (Brown et al., 2005; Gent et al., 
2002). Evidence supporting this model includes co-immunoprecipitation studies showing 
that a portion of GHR exist as constitutive dimers in vitro (Brown et al., 2005; Gent et al., 
2002). Evidence supporting the model that a conformational change of the receptor is 
needed for activation rather than homodimerisation includes the lack of receptor activation 
by dimerisation alone, and the observation that inducing a rotation of the intracellular 

















Both models however predict that dimerisation/rotation of the receptors once bound by GH 
results in tyrosine kinase activation. As stated before, GHR lacks intrinsic kinase activity and 
therefore relies on intracellular tyrosine kinases in order to achieve signal initiation in 
response to GH. GHR has been shown to signal primarily through members of the Janus 
tyrosine kinase (JAK) family (Argetsinger et al., 1996). Members of the JAK family include 
JAK1, JAK2, JAK3, and Tyk2. Two characteristics are shared amongst these members; (i) the 
absence of SH2 or SH3 domains, (ii) and the presence of seven conserved JH regions, JH1-7, 
of which JH1 is the functional catalytic domain and JH2 is the inhibiting pseudokinase 
domain (Zhu et al., 2001). 
 
Upon binding of GH, the dimerisation/conformational change of receptors allows for the 
spatial repositioning of GHR-associated JAKs bound to Box 1, which results in the disruption 
of the ability of JH2 domains to inhibit catalytic JH1 domains, thus leading to JAK activation 
(Saharinen et al., 2000; Zhu et al., 2001). Since JAK family members lack SH3 domains, which 
typically bind proline rich domains, it is possible that JAK kinases associate with GHR through 
a SH3 domain-containing adaptor protein (Finidori, 2000). Activation of receptor-associated 
JAK in response to GH results in JAK and GHR phosphorylation (Fig.7) (Argetsinger et al., 
1996). GH induces mostly JAK2 phosphorylation, while JAK1 and JAK3 show minimal 
phosphorylation, indicating that GH signalling is primarily mediated by JAK2, and to a lesser 
extent by JAK 1 and JAK3 (Carter-Su et al., 1996; Johnston et al., 1994; Smit et al., 1996). 
Phosphorylation of JAK and of the intracellular domain of GHR by JAK, particularly JAK2, 
serves to provide docking sites for SH2 domain-containing proteins recruited to mediate 














Figure 7: JAK2 activation by GH and subsequent intracellular phosphorylation of GHR and STAT5 (Brooks et al., 
2008).Binding of GH to GHR dimers initiates the dissociation of the pseudokinase (JH2) domain from the functional kinase 
domain (JH1). Phosphorylation of tyrosine residues (Y) on GHR and JAK2 then occurs, allowing for the association of SH2 
























Several proteins are recruited and/or activated directly or indirectly by GHR using JAK to 
achieve downstream GH signalling. These molecules include Src homology 2/α collagen 
related (SHC) protein (VanderKuur et al., 1995), insulin receptor substrate (IRS) 
proteins(Yamauchi et al., 1998), SH2 domain-containing protein tyrosine phosphatase-1 and 
-2 (SHP-1 and SHP-2)(Ram and Waxman, 1997), the p58 subunit of phosphoinositide-3 kinase 
(PI3K ) (Moutoussamy et al., 1998), epidermal growth factor receptor (EGFR )(Yamauchi et 
al., 1997), and signal transducers and activators of transcription (STAT-1, -3, and -5) (Ram et 
al., 1996; Smit et al., 1996; Sotiropoulos et al., 1996) amongst others. Recruitment of the 
various signalling molecules results in the activation of several pathways allowing for the 
pleiotropic effects of GH (Fig.8).For example, association of focal adhesion kinase (FAK) to 
phosphorylated and thus activated JAK2 in response to GH results in activation of FAK and 
thus alterations to cytoskeletal structure (Zhu et al., 1998). Also, the MAPK/ERK and PI3K 
pathways are known to be activated in response to GH. The activation of ERK via the SHC, 
Grb2, Ras, Raf and MEK cascade is well known (Lewis et al., 1998). GHR has been shown to 
use this cascade to activate ERK1/2 (Fig.8) (Winston and Hunter, 1995). Activation of ERK1/2 
ultimately results in the transcription of several genes encoding transcription factors 
including c-fos, junB, and egr-1, amongst others (Fig.8) (Hodge et al., 1998). GH-stimulated 
activation of PI3K has been shown to be mediated by GHR-activation of IRSs, specifically IRS-
1 and IRS-2 (Fig.8) (Yamauchi et al., 1998; Yenush and White, 1997). PI3K activation then 
activates Akt to bring about changes in metabolism and the generation of anti-apoptotic 
signals (Costoya et al., 1999). GH-stimulated activation of PI3K has been shown to be 
important for cell proliferation, survival, cytoskeletal reorganisation, and cellular 
metabolism, further potentiating the pleiotropic effects of GH (Yenush and White, 1997). 
 
Several genes are induced by these pathways, chief among is the igf1 gene which encodes 
for the mitogen IGF1 (Murphy et al., 1987). Additionally, several genes encoding for 
suppressor of cytokine signalling (SOCS) proteins are also induced (Adams et al., 1998; 
Tollet-Egnell et al., 1999). Also, the genes of c-jun (Gurland et al., 1990)and c-myc (Murphy 














Figure 8: Activation of several intracellular signalling pathways by GHR (Rosenfeld et al., 2007). Activation of GHR by GH 
results in JAK2 and GHR phosphorylation. This in turn provides docking sites for a number of signalling molecules, ultimately 



























Of all the targets of GHR signal transduction in response to GH, none is more studied than 
the STATs. STATs are SH2 domain-containing, cytoplasmic factors that are important in 
binding and inducing transcription of GH-responsive genes (Herrington et al., 2000). STAT 
transcription factors are recruited to the proximity of JAKs by binding via their SH2 domains 
to phosphorylated tyrosine residues on the intracellular domain of GHR (Fig.7 )(Herrington et 
al., 2000; Zhu et al., 2001). They are then initially activated by phosphorylation by JAKs, 
followed by serine phosphorylation (Fig.7) (Herrington et al., 2000; Ram et al., 1996; Zhu et 
al., 2001). Several different STAT transcription factors exist, however, only STAT-1, STAT-3, 
STAT-5a, and STAT-5b are activated in response to GH (Sotiropoulos et al., 1996; Waxman et 
al., 1995a). Once activated, STAT transcription factors then dissociate from the receptor, 
either homo- or heterodimerise with each other, translocate to the nucleus, bind to their 
appropriate DNA response elements, and thereby drive transcription of various genes (Fig.8) 
(Ihle, 1996; Zhu et al., 2001). Promoter response elements to which STAT transcription 
factors bind include growth hormone responsive elements (GHRE) and INFγ activated 
sequence (GAS)-like elements(Fig.8). Genes with these response elements in their promoters 
include c-fos (Meyer et al., 1994), insulin 1 (Galsgaard et al., 1996), spi 2.1 (Bergad et al., 
1995), als (Ooi et al., 1997), and several P450 genes encoding for members of the CYP2 and 
CYP 3 family (Waxman et al., 1995b). 
 
In summary, GH achieves its pleiotropic cellular response by activating several complex 
intracellular signalling pathways. By binding to GHR, GH initiates intracellular tyrosine 
phosphorylation, primarily by JAK2. This then allows the recruitment and activation several 
different signalling molecules. These then activate multiple complex signalling pathways that 
affect a wide range of cellular functions. Multiple genes are also induced by this manner 




















1.5.4Post-Transcriptional Regulation of GHR Protein Expression and Signalling 
 
Considering that activation of GHR leads to alterations of such a wide variety of key cellular 
functions, it should be unsurprising that the GH/GHR signalling axis is tightly regulated at 
different levels. Firstly, as mentioned before, regulation occurs at the ligand stage; free GH 
available to bind GHR expressed on target tissues is already tightly regulated in serum by 
binding to GHBP. Other methods include inducing signalling suppressor proteins in response 
to GH, ligand–dependent and –independent internalisation of the receptor, shedding of the 
receptor at the cell surface, and interaction of full-length GHR with dominant negative 
isoforms of the receptor amongst others, all of which are described in more detail below. 
 
Roughly 50% of all circulating GH is bound by GHBP thus preventing it from binding to GHR 
and inducing signalling (Baumann et al., 1988). GHBP corresponds to the extracellular 
domain of the full length receptor, and binds to GH in the 2:1 stoichiometry seen with GH 
binding to full-length GHR (Baumann et al., 1994; Leung t al., 1987). GHBP is generated 
differently in different species. For example, in rodents, GHBP is generated by alternative 
splicing of GHR mRNA resulting in the soluble form of the extracellular domain of full-length 
GHR (Baumbach et al., 1989). In humans, GHBP is derived by the proteolytic shedding of the 
extracellular domain of full-length GHR present on the cell surface (Alele et al., 1998). A 
known by-product of this shedding is the intracellular domain of the receptor (Alele et al., 
1998). The proteolytic cleavage of surface-expressed GHR involves the action of tumour 
necrosis factor-α-converting enzyme (TACE), a known transmembrane metalloprotease 
(Alele et al., 1998; Zhang et al., 2000). This soluble form of the extracellular domain is then 
released into the bloodstream where it is free to bind GH. GHBP therefore negatively 
regulates GH signalling in two ways in humans; (i) it actively binds free GH in serum thereby 
limiting the amount of free GH able to bind to GHR, (ii) generation of GHBP results from 

















Furthermore, binding of GH to GHR on the cell surface not only results in signal initiation and 
transduction, but also the internalisation and subsequent lysosomal degradation of the 
activated receptor, thereby preventing over-activation of GHR (Murphy and Lazarus, 1987). 
Subsequent studies have shown that the UbE motif and a functional ubiquitin conjugating 
system is needed for ligand-induced endocytosis and degradation of the receptor (Kerkhof et 
al., 2007; Strous et al., 1996). Very little else is known about the process by which GH-
binding leads to GHR endocytosis and degradation, however, it is proposed that binding of 
GH leads to the docking of ubiquitin conjugases and ligases onto the UbE motif, and the 
subsequent ubiquitination of GHR. Clathrin-coated endocytosis machinery is activated and 
results in the transport of GHR to early and late endosomes (Vleurick et al., 1999). The GH-
GHR complex is then degraded (Strous et al., 1996). Additionally, there is evidence that GHR 
may undergo internalisation in a ligand-independent manner in similar fashion as described 
above (Kerkhof et al., 2007). By this poorly-understood mechanism, ligand-dependent and –
independent GHR internalisation and degradation occurs to further regulate GHR levels and 
activity. 
 
GHR signalling is also suppressed by several members of the SOCS family. SOCS members 
contain a central SH2 domain and a highly conserved SOCS box (Chen et al., 2000). The 
mechanism by which SOCS members suppress cytokine signalling remains poorly 
understood, but there is evidence that this occurs via suppression of JAK2 signalling by direct 
binding to the tyrosine residue (Y1007) of the activation loop of JAK2 through its SH2 domain 
(Yasukawa et al., 1999). It is suggested that this interaction inhibits the catalytic activity of 
JAK2 (Yasukawa et al., 1999). As stated before, GH is known to induce expression of SOCS-1, 




















Several isoforms of GHR exist (Amit et al., 1997; Ballesteros et al., 2000; Ross et al., 1997; 
Urbanek et al., 1993). These isoforms will be discussed in greater detail later. Interestingly 
though, one of these isoforms has been shown to function as a dominant negative inhibitor 
of full-length GHR, adding to the several avenues already utilised to regulate signalling by 
GHR (Ross et al., 1997). This isoform of the receptor, GHR 1-279, lacks 97% of the 
intracellular domain, including the bulk of exon 9 and the whole of exon 10, and is therefore 
more akin to GHBP (Ross et al., 1997).It does not however lack the transmembrane region 
needed for cell surface anchorage, and is therefore found on the cell surface (Ross et al., 
1997). Its suppressive effect has been shown to occur partly by suppression of downstream 
signalling, however, it may also exert its suppressive effects by competing with full-length 
GHR for GH binding when forming homodimers (Ross et al., 1997). 
 
Since GHR levels are so tightly regulated by ubiquitination, it spends a very short time 
expressed at the cell surface as a fully-mature, glycosylated receptor. The half-life of human 
GHR is not clear, some studies have seen a half-life of 2 hours (Amit et al., 1997), while 
others showed a half-life of about 1 hour in physiological conditions (Deng et al., 2007; 
Pilecka et al., 2007). Its short half-life is further shortened with increasing GH availability 
(Deng et al., 2007), while its short half-life is further demonstrated as the half-life of rat GHR 
in vivo is 45 minutes (Gorin and Goodman, 1985). Regulation is further enforced if the 
receptor escapes ligand-independent ubiquitination. Binding of GH induces the expression of 
SOCS, while dimerisation with the GHR 1-129 isoform renders a signalling-compromised 
dimer. These mechanisms of GHR protein regulation remain poorly defined, but despite this, 






















1.5.5 GHR Isoforms 
 
Besides full-length GHR, only three isoforms of GHR have been characterised. These isoforms 
include the d3GHR (Urbanek et al., 1993), 1-277 GHR (Ross et al., 1997), and 1-279 GHR 
(Amit et al., 1997; Ross et al., 1997). The isoforms are structurally unique from each other, 
and also have unique binding affinities and activation characteristics. The 1-277 and 1-279 
GHR isoforms are structurally the most similar since both lack approximately 97% of the 
intracellular domain (Fig.9) (Ross et al., 1997). Since expression of GHR is ubiquitous, the 1-
277 and 1-279 GHR isoforms are expressed in a wide variety of target tissues, including liver, 
adipose, muscle, heart, prostate, and kidney tissue (Ballesteros et al., 2000). Tissue-specific 
expression of the d3GHR isoform is less known and has only been reported in breast cancer 
cell lines and liver tissue (Decouvelaere et al., 1995). 
 
Figure 9: Schematic of full-length GHR and the 1-277 and 1-279 GHR isoforms (Ross, 1999). 
The 1-279 GHR isoform arises from utilising an alternative 3’-acceptor splice site in exon 9, 
which results in losing most of exon 9, and the entire exon 10, ultimately resulting in the loss 
of 97% of the intracellular domain. The splice site occurs 26bp downstream in exon 9, and 
utilisation of this splice site results in a frame shift and therefore the insertion of a 
premature stop codon within exon 9 (Ross et al., 1997).The resulting transcript encodes the 












intracellular domain (Fig.9) (Ross et al., 1997). 1-277 GHR arises in a similar manner except 
that exon 9 is totally skipped, resulting in a frame shift and thus insertion of a premature 
stop codon in exon 10 (Ross et al., 1997). Once again, the resulting transcript encodes the 
whole extracellular and transmembrane domain, with only the first 7 amino acids of exon 10 
(Fig.9) (Ross et al., 1997). 
Of these two, similar isoforms, only the 1-279 GHR isoform has been studied further. 
Homodimers of this isoform undergo minimal internalisation and are not down regulated in 
response to GH, showing a half-life as long as 4 hours. They also showed an increased 
capacity to generate GHBP (Amit et al., 1997). Similar findings were seen in another study, 
however, it was also shown that the 1-279 GHR isoform had a reduced affinity for GH but 
increase capacity to bind GH by having more binding sites when compared to full-length GHR 
(Ross et al., 1997). It was also shown that heterodimers of 1-279 GHR and full-length GHR 
may exist. Given that the isoform lacks the intracellular domain, these heterodimers were 
unable to signal in response to GH (Ross et al., 1997). The 1-279 GHR isoform has therefore 
been shown to act as a dominant negative inhibitor of full-length GHR. 
The other remaining isoform, d3GHR, arises by skipping exon 3, through homologous 
recombination which mimics alternative splicing between the retroviral retroelements 
flanking exon 3 (Pantel et al., 2000). The loss of exon 3 by this mechanism results in a A6D 
substitution in exon 2 (Dos Santos et al., 2004). The substitution of this highly conserved 
amino acid results in altered charge and hydrophobicity of the isoform compared to full-
length GHR (Dos Santos et al., 2004). Little else is known about this isoform. Interestingly 
though, it has been shown by several studies that the d3GHR isoform shows increased 
responsiveness to GH in vivo, compared to full-length receptor (Binder et al., 2006; van der 
Klaauw et al., 2008; Dos Santos et al., 2004). The mechanism resulting in increased 
responsiveness of d3GHR remains unknown. However, it is thought that the removal of the 
N-terminal loop encoded by exon 3 results in a subtle conformational change in the 
extracellular domain that may facilitate increased responsiveness to GH binding (Dos Santos 














1.6 GH/IGF1 Axis in Cancer 
As stated before, the GH/IGF1 axis is well described in a number of cancer models. Given 
that the original hypothesis of GH action on growth and proliferation was that GH stimulates 
the hepatic secretion of IGF1, which then functions in an endocrine manner to bind to IGF1 
receptors in tissues to induce growth, it was thought that GH exerts its proliferative and 
growth effects through its physiological effector IGF1. IGF1 is known to act on many cell 
types to bring about increased proliferation and anti-apoptotic signals through its activation 
of MAPK and PI3K pathways respectively (Gooch et al., 1999). It is therefore unsurprising 
that elevated levels of IGF1 have shown to confer an increased risk of breast (Yee et al., 
1989), endometrial (Elkas et al., 1998), pancreatic (Bergmann et al., 1995), lung (Minuto et 
al., 1986), colorectal (Rinaldi et al., 2010), and prostate cancer (Rowlands et al., 2009). As 
described previously, carcinogenesis is the multistep process whereby normal cells 
accumulate a number of cancerous traits through genomic “hits”. Therefore, the hypothesis 
of the link between elevated IGF1 levels and cancer was that rather than IGF1 directly 
initiating carcinogenesis, it indirectly promoted carcinogenesis by increasing the pool of 
partially transformed cells available to receive the necessary genomic “hits” to become 
cancerous, and this was through the proproliferative and anti-apoptotic actions of IGF1. 
GH, since it promotes the production and secretion of IGF1, also plays a role in 
carcinogenesis, albeit initially thought to be an indirect role. GH has been shown to be an 
etiologic factor in tumourigenesis. Early animal model studies have shown that GH induced 
neoplasms in rats (Moon et al., 1950), while transgenic mice overexpressing human GH 
showed higher incidences of tumours in mammary glands and livers (Snibson et al., 2001; 
Törnell et al., 1992). Also, in humans, a condition exists resulting in increased GH and 
therefore IGF1 levels (Chhabra et al., 2011). These elevated levels are as a result of either 
pituitary tumours, or activating mutations in the GHRH signalling cascade, which result in 
hypersecretion of GH by pituitary somatotroph cells (Chhabra et al., 2011). The condition is 
associated with an increased risk of colon (Ezzat et al., 1991), breast (Cheung and Boyages, 
1997), and prostate cancer (Colao et al., 1998; le Roux et al., 2000). Given that IGF1 has been 
shown to play a role in these cancers, it was therefore initially thought that the tumourigenic 
effects of GH were indirectly mediated by IGF1 rather than directly by GH. Studies have 
confirmed this as mice treated with GHR antagonist resulted in a decrease of tumour 












showed that antagonism of GHR resulted in regression of meningioma xenografts in nude 
mice, with only a 20% decrease in serum IGF1 (McCutcheon et al., 2001). This indicates that 
GH may in fact ellicit its tumourigenic effects directly through GHR, and not via IGF1. 
Recently, studies have been conducted to elucidate the mechanism whereby GH may 
promote tumourigenesis. Such studies have shown that GH overexpression promotes 
proliferation (Chiesa et al., 2011; Kaulsay et al., 1999; Pandey et al., 2008; Segard et al., 
2003; Zhu et al., 2005), anchorage-independent growth (Pandey et al., 2008), cell migration 
and invasion (Pandey et al., 2008), epithelial-to-mesenchymal conversion (Pandey et al., 
2008), angiogenesis (Brunet-Dunand et al., 2009), and chemoresistance (Minoia et al., 2012; 
Zatelli et al., 2009) while inhibiting apoptosis (Segard et al., 2003) and differentiation (Segard 
et al., 2003), mostly within in vivo models. In these studies, the phenotypes achieved by 
overexpressed GH were seen with alterations to a wide range of cellular functions. 
Overexpressed GH was associated with increased transcription of several oncogenes 
including hoxa1, myc, and jun (Pandey et al., 2008). The gene encoding human telomerase, 
hTERT, and the gene encoding Cyclin D1 were also seen to be induced in response to 
overexpressed GH (Pandey et al., 2008), along with c-fos (Zatelli et al., 2009)and JNK (Minoia 























1.7 GHR in Cancer 
GHR has been reported to be overexpressed in number of cancers, including breast (Gebre-
medhin et al., 2001), adrenocortical (Lin et al., 1997), colon (Yang et al., 2004), and 
melanoma (Lincoln et al., 1999).Additionally, in some of the studies showing the 
tumourigenic effects of GH, these effects have been shown to be mediated largely by GHR, 
by using the GHR antagonist, G120R, that is known to bind selectively to GHR and not PRLR 
(Goffin et al., 1999; Kaulsay et al., 1999; Minoia et al., 2012; Pandey et al., 2008). However, 
the tumourigenic effects of GH have also been shown to be mediated by PRLR, albeit to a 
lesser extent than GHR (Xu et al., 2011). Given the tumourigenic effect of GH seen in various 
cancer cell lines, GHR antagonism was shown to inhibit tumour growth in vitro (McCutcheon 
et al., 2001). This, in combination with the observed tumourigenic role of GH, indicates that 
GH elicits its tumourigenic effects largely through GHR, however, GH signalling via PRLR 
cannot be completely excluded. 
Interestingly, nuclear-localised GHR is a common feature of tissues and cells exhibiting a high 
rate of proliferation (Conway-Campbell et al., 2007; Lincoln et al., 1998).  Accumulation of 
GHR within the nucleus has been reported in a number of cancers including B-cell 
lymphomas, mammary carcinoma, and melanoma (Lincoln et al., 1998). Full-length GHR has 
been demonstrated to localise to the inner and outer nuclear membranes, nucleoplasm, and 
chromatin to achieve its GH-stimulated function within the nucleus (Lobie et al., 1994). 
Additionally, when nuclear-localised GHR was expressed within the immortalised pro-B cell 
lineBaF3, aggressive metastatic tumours were generated in vivo when injected into mice 
(Conway-Campbell et al., 2007). These findings suggest a role for nuclear-localised GHR in 
tumourigenesis. Further circumstantial evidence is the observation that 75% of women with 

















1.8 Project Aim and Objective 
 
The aim of this project is to investigate the role of GHR in oesophageal squamous-cell 
carcinoma (OSCC) carcinogenesis. This is based on the observations that GH plays a role in a 
number of cancers, and that its carcinogenic effects is largely mediated through GHR. This 
will be done by; 
 
(1) Investigating the expression of GHR and GH mRNA in a panel of OSCC cell lines. 
(2) Investigating the expression of GHR protein in a panel of OSCC cell lines. 
(3) Investigating the effect of GHR knockdown on carcinogenesis by measuring 



























GH & GHR EXPRESSION 
 
To investigate the potential role of GHR and autocrine GH, OSCC cell lines underwent mRNA 
analysis for the identification of GH and GHR mRNA expression by means of PCR, followed by 
immunoblotting and immunocytochemistry. The human breast cancer cell line T47D was 
used as the positive control for the mRNA expression of GH, GHR (Decouvelaere et al., 
1995), and d3GHR. mRNA expression of GH and d3GHR have not been shown previously in 
T47D, however, while conducting initial PCRs, it was found that the expected PCR products 
for GH and d3GHR cDNA were amplified from T47D cells. Thus, T47D from then on served as 
the positive control for all PCRs. 
2.1 mRNA Expression Profile 
2.1.1 Primer Design 
To identify the expression of GH, full-length GHR (flGHR), and the d3GHR isoform, gene-
specific primers that have previously been published were used. All primers used were 
intron-spanning and thus were able to distinguish between genomic DNA (gDNA) and cDNA 
reverse transcribed from messenger RNA (mRNA). The GH-specific primers were directed 
towards selected regions within exons 3 and 5 (Kaulsay et al., 1999). The flGHR-specific 
primers were specific for flGHR cDNA and excluded amplification of cDNA of the 1-277, and 
1-279 GHR splice variants, but allowed amplification of d3GHR cDNA (Fig.10). These primers 
were directed towards regions within exon 6 and 9 (Kaulsay et al., 1999). The d3GHR-specific 
primers were directed towards exons 2 and 5 and amplified cDNA from all splice variants, 














Figure 10: Annealing position of the GHR primers used. Exons are shown as boxes, primers as arrows, exon boundaries as 
slashes, deleted sections by periods, and inframe stop codons underlined. 
Since the flGHR forward primer anneals within exon 6, and since exon 6 is unaltered in 
flGHR, 1-277, and 1-279 GHR, the flGHR-specific reverse primer had to be able to distinguish 
between flGHR and the mentioned isoforms. Hence, the reverse primer anneals in a portion 
of exon 9 that is completely lost in the 1-277 GHR isoform, and partly lost in the 1-279 GHR 
isoform (Fig.10). Specifically for the 1-279 GHR isoform, the primer did anneal to the very 
little of exon 9 that remained in the 1-279 isoform, however, the first 4 nucleotides of the 3’ 
end of the primer did not anneal, therefore preventing the amplification of 1-279 GHR 
mRNA. Since d3GHR primers annealed to exons 2 and 5, and since exon 3 was lost in the 
d3GHR isoform and present in all other isoforms of GHR, these primers were only able to 
distinguish d3GHR from all other isoforms (Fig.10). 
2.1.2 DNase Treatment 
As stated above, all primers used did span introns, thus allowing the distinction between 
gDNA and mRNA. Of the 4 PCRs done (GH, flGHR, d3GHR, GAPDH), only the GH-specific 
primers were able to generate a gDNA product small enough to be effectively amplified and 
observed following agarose gel electrophoresis (Fig.11A). Sizes for gDNA bands using the 4 
gene-specific primers were 688bp, 27 736bp, 129 186bp, and 5 210bp for GH, flGHR, d3GHR, 
and GAPDH gene-specific primers respectively. Contamination by gDNA in RNA preparations 












large gDNA products that were unable to be visualised following agarose gel electrophoresis. 
An appropriate DNase treatment protocol was implemented to remove contaminating 
gDNA. 
 
Figure 11: Identification and removal of gDNA contamination following RNA isolation. (A) RNA from T47D was isolated, 
DNase treated, converted into cDNA, amplified by PCR, electrophoresed, and visualised as in materials and methods.PCR 
using GH-specific primers indicating gDNA contamination product band.(B) RNA after DNase treatment and inactivation by 
three different methods; (i) 1-bromo-3-chloropropane separation, (ii) heat inactivation, (iii) addition of Inactivation 
Reagent. 1µg of untreated, DNase-treated, and DNase-inactivated RNA was loaded on an RNA gel and electrophoresed as in 
materials and methods. However, 2µg of DNase-treated RNA was loaded in the DNase treated lane of the Inactivation 
Reagent method. Dotted lines indicate where different images of different RNA gels have been attached. (C) GH PCR 
following DNase treatment and inactivation by BCP separation and addition of Inactivation Reagent. DNase-treated RNA 
















RNA was incubated with a commercially available DNase which was then inactivated by one 
of the following three methods; (i) by means of 1-bromo-3-chloropropane (BCP) separation, 
(ii) by heat inactivation, (iii) by the addition of the Inactivation Reagent supplied with the 
DNase treatment kit. Spectrophotometric analysis indicated a 5% loss of RNA directly 
following DNase treatment, and this is further supported by the visual loss in intensity of 28S 
and 18S bands following RNA gel electrophoresis (Fig.11B). This loss is most likely due to 
handling of the sample during DNase treatment as evaporation and/or degradation may take 
place during the incubation step of the digest.  
Spectrophotometric analysis after DNase treatment and inactivation indicated that there 
was a 90%, 100%, and 13% loss of starting RNA material when the DNase enzyme was 
inactivated by BCP separation, heat inactivation, and the addition of Inactivation Reagent, 
respectively. This loss was further confirmed by visual inspection of the of 28S and 18S bands 
following electrophoresis(Fig. 11B). 
RNA treated with DNase and then inactivated by either BCP precipitation or addition of 
Inactivation Reagent then underwent cDNA conversion and GH PCR as described in materials 
and methods. The 688bp band was once again observed before DNase treatment indicating 
possible gDNA contamination, with the desired 343bp also being observed, albeit at low 
levels (Fig.11C). Following DNase treatment and DNase inactivation by BCP separation, no 
bands were seen to be amplified (Fig.11C), probably due to the significant loss of RNA using 
this method. However, following DNase treatment with inactivation by means of Inactivation 
Reagent, only the desired 343bp band possibly corresponding to GH mRNA was seen 
(Fig.11C). Sequencing of this band at a later stage indicated the 343bp band is human GH 
(Appendix A). The loss of the 688bp band following DNase treatment indicates that it does 
correspond to gDNA contamination within the RNA preparation, and that it is effectively 
removed with DNase treatment. The increase in intensity of the 343bp band could be as a 
result of a more efficient PCR reaction following the removal of gDNA contamination. This 
allows for the finite amounts of primers and nucleotides added to the PCR reaction to 
amplify only cDNA targets rather than both cDNA and gDNA targets. However, PCR for a 
housekeeping gene was not included here, and therefore the increase in the 343bp band 













2.1.3 GH & GHR mRNA Expression 
Since an appropriate DNase treatment protocol was established, RNA isolated from a panel 
of OSCC cell lines and fibroblast cells was DNase treated, reverse transcribed, and finally 
amplified by PCR with the gene-specific primers for GH, flGHR, and d3GHR (Fig.12).A panel of 
nine human OSCC cell lines (WHCO1, WHCO5, WHCO6, Kyse 30, Kyse 70, Kyse 150, Kyse 180, 
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Figure 12: mRN A expressi on of GH and GHR in osee cell li nes and immortalised fibrobl ast cells. RN A was isolated, DNase treate d , and converted into eDNA as described in materia ls and 
methods, followed by PCR using gene-specific prim ers for GH, f1 GHR, d3GHR, and GAPDH. PCR products were then electrophoresed in a 1% aga r-ose gel and visualised as described in materials 
and methods. Dottf'd lines indica t (> where lanes hav(' been omitted. Using the f1GHR prim er set, a band of 456bp corr esponding to f1GHR and d3GHR eDNA was amplified. Using th (> d3GHR 












PCR for the housekeeping gene GAPDH amplified the expected 201bp product in all cell 
lines, indicating that the cDNA was of reasonable quality (Fig.12). As expected, following PCR 
for GH and flGHR in T47D, products of 343bp and 456bp in size were generated respectively 
(Fig.12). Sequencing of these PCR products revealed that the 343bp and 456bp products 
corresponded to human GH and GHR (flGHR and d3GHR) respectively (Appendix A). Using 
d3GHR-specific primers generated 420bp and 354bp products in T47D (Fig.12). Sequencing 
of these two products indicated that the 420bp correlated to GHR, either flGHR, 1-279, or 1-
277 GHR, while the 354bp correlated to d3GHR mRNA (Appendix A). 
PCR using the GH-specific primers showed amplification of the expected 343bp band in five 
of the nine OSCC cell lines (WHCO5, Kyse 70, Kyse 150, Kyse 180, and Kyse 520), conclusively 
showing ectopic expression of GH mRNA in these cell lines (Fig.12). Interestingly, of the 
fibroblast cell lines, FG0 also showed GH mRNA expression (Fig.12). The 456bp band 
correlating to both flGHR and d3GHR mRNA was seen in seven of the nine OSCC cell lines 
tested (WHCO5, WHCO6, Kyse 30, Kyse 70, Kyse 180, Kyse 450, and Kyse 520) while both 
fibroblast cell lines also expressed flGHR and/or d3GHR (Fig.12). Using the d3GHR-specific 
primers that are able to distinguish between GHR and d3GHR indicated that GHR was 
expressed in five of the nine OSCC cell lines (WHCO5, Kyse 70, Kyse 180, Kyse 450, and Kyse 
520) and in both of the fibroblast cell lines (Fig.12). Whether this correlated to flGHR, 1-279, 
or 1-277GHR could not be determined. However, given that in previous studies it was found 
that 1-279 and 1-277 GHR made up 10% and less than 1% of total GHR mRNA transcripts 
respectively in human liver cells (Ross et al., 1997), it can be argued that the 420bp product 
corresponds mostly to flGHR mRNA. d3GHR mRNA was only conclusively seen to be 
expressed in three of the OSCC cell lines (WHCO5, WHCO6 and Kyse 30), and only in DMB of 
the normal fibroblast cell lines (Fig.12).d3GHRmRNA was seen to be expressed by WHCO6 
when performing the second d3GHR PCR (data not shown). 
Since GHR is a ubiquitously expressed receptor, it should be unsurprising that it is expressed 
in a majority of OSCC cell lines and in both the normal fibroblast cell lines. However, it is 
interesting to note that of the seven OSCC cell line shown to express GHR, only two express 
mRNA for the d3GHR isoform. With the ectopic expression of GH mRNA shown in a majority 
of OSCC cell lines tested, along with the expression of GHR mRNA, indicates a possible role 












lines tested. This could also be true for the fibroblast cells used here since FG0 also showed 
extra-pituitary expression of GH mRNA. Additionally, the detection of d3GHR in two of the 
nine OSCC cell lines tested indicates that d3GHR may play a role in a subset of patients, since 
these cell lines originate from patients.  
2.2 GHR Protein Expression 
2.2.1 Western Blotting on Cell Lines Transiently Overexpressing GHR 
Since a cell line that had previously been shown to express GHR was not available, western 
blots were optimised using lysate from cells transiently overexpressing GHR as a positive 
control. Both GHR antibodies (Mab 263 and B12) were tested by straight immunoblotting 
using lysates from the overexpressing cell lines (Fig.13) 
 
Figure 13: Characterising the GHR protein band using cell lines transiently overexpressing GHR. Protein from Kyse 150 and 
COS 1 cells that were transiently transfected with GHR was isolated, and analysed by western blot as described in materials 
and methods. β-Tubulin was included as a control for protein loading. Sizes of bands are indicated. Depicted results are 
representative of two separate experiments. (A)Protein isolated from GHR-overexpressing (Kyse 150+GHR) and non-
overexpressing Kyse 150 cells (Kyse 150) was electrophoresed and underwent immunoblotting with the GHR antibody B12. 
(B) Protein isolated from GHR-overexpressing (COS 1+GHR) and untransfected COS 1 cells (COS 1) was electrophoresed and 
underwent immunoblotting with the GHR antibody Mab 263. (C) Protein isolated from GHR-overexpressing (COS 1+GHR) 
and untransfected COS 1 cells (COS 1) was electrophoresed and underwent immunoblotting for the HA tag. Additionally, as 
a control for the HA antibody, COS 1 cells were transfected with a Tbx2 expression plasmid known to encode HA-tagged 












Kyse 150 cells, previously shown not to express GHR mRNA, were transiently transfected 
with the GHR expression plasmid (GHR-pcDNA3.1). Lysates from untransfected and 
overexpressing cells underwent SDS-PAGE electrophoresis and immunoblotted with the B12 
GHR antibody. GHR overexpression resulted in the detection of two protein bands at 110kDa 
and 72kDa in size (Fig.13A). The 110kDa band likely corresponds to full-length GHR. Since the 
B12 antibody recognises the intracellular domain of GHR, the 72kDa band was likely the 
cytoplasmic tail remnants following cell-surface cleavage of GHR, since previously a similar 
sized band was detected using a similar antibody as the cytoplasmic remnant (Schantl et al., 
2004). The 72kDa band seen following GHR overexpression is unlikely to be a splice variant 
of GHR as alternative splicing of cDNA-containing plasmids is highly unlikely. Also, the 
induction of the 72kDa band due to the stresses of transfection was also disproved when 
transfecting with empty pcDNA3.1 vector (Appendix A). Similar results were seen when 
immunoblotting GHR-overexpressing and untransfected COS 1 cells with the Mab 263 
antibody, except that a 75kDa band was seen in untransfected cells, while overexpression 
introduced only a 110kDa band (Fig.13B). Interestingly, this 75kDa band decreased in 
intensity following GHR overexpression. Since β-Tubulin immunoblotting shows even protein 
loading, the decrease in the 75kDa band is quite intriguing.  
Since the GHR protein encoded by the GHR-pcDNA3.1 plasmid is HA-tagged, protein lysates 
from COS 1 overexpressing and untransfected cells were immunoblotted with an antibody 
directed against the HA tag (Fig.13C). Once again, a 110kDa band was detected following 
GHR overexpression with two other protein bands being observed at 62kDa and 38kDa. 
However, detection for HA-tagged proteins failed to identify any proteins at 72kDa in size 
indicating that the HA tag was likely attached on the extracellular domain of GHR as the 
72kDa band likely corresponded to the intracellular domain of GHR. Since information on the 
cloning of the GHR-pcDNA3.1 plasmid was unavailable, this is the likely scenario. As a control 
for the HA antibody, COS 1 cells were transfected with an expression plasmid known to 
encode for HA-tagged Tbx2 protein (Fig.13C). Tbx2 overexpression resulted in the detection 
of the expected 100kDa band. Control for loading was not conducted, however, based on 
the even intensity of the non-specific bands between lanes, it may be inferred that loading 
was even. This implies that all bands observed are as a result of transfection and not 












band following Tbx2 transfection, indicated that the system for transfection and 
immunoblotting, was functional. 
Given that all three antibodies detected a 110kDa band following GHR overexpression, and 
that protein loading is even, the 110kDa is most likely GHR, even with the size being smaller 
than the reported 120-130kDa size for mature GHR (Asa et al., 2007; Kerkhof et al., 2007; 
Ross et al., 1997; Stubbart et al., 1991; Wang et al., 1992). To further support this, 100 
copies of the GHR-pcDNA3.1 expression plasmid underwent PCR using the flGHR-specific 
primers, and the PCR product sequenced. Sequencing revealed that the insert of the plasmid 
was in fact human GHR cDNA (Appendix A). 
2.2.2 Expression of GHR in Oesophageal Squamous-Cell Carcinoma Cell Lines 
Since immunoblotting on GHR overexpressing cell lines indicated that GHR was detected at 
110kDa using both GHR antibodies, crude protein lysate extracts from OSCC cell lines and 
fibroblast cells were then tested for GHR protein expression using both GHR antibodies 
(Fig.14). Protein lysate from GHR-overexpressing Kyse 150 cells (Kyse 150+GHR) was 
analysed, while T47D cells was included as a positive control as T47D cells have previously 

















Figure 14: GHR expression in OSSC cell lines and fibroblast cells. 30µg of crude lysate from indicated cell lines were 
immunoblotted for GHR as described in materials and methods. β-Tubulin was included as a control for protein loading. 
Sizes of bands are indicated. Depicted results are representative of two separate experiments.(A) Immunoblotting with the 
GHR antibody Mab 263. (B) Immunoblotting with the GHR antibody B12. 
Once again, the expected 110kDa band was observed following GHR overexpression (Kyse 
150+GHR lane) and detection with the Mab 263 antibody (Fig.14A). However, this band was 
not seen in any of the other cell lines tested when probed with the same antibody. A 75kDa 
band was seen in all but two cell lines (WHCO5 and Kyse 150) (Fig.14A). The possibility of the 
75kDa band being an isoform of GHR, or perhaps an unglycosylated, precursor form of the 
receptor, may not be excluded. The epitope for the Mab 263 has been previously mapped 
and found to lie around the binding region of GH (Wan et al., 2003), and therefore should be 
able to detect both 1-279 and 1-277 GHR isoforms along with flGHR. However, since 1-
279GHR was detected at 55-60kDa, and since one would expect to observe 1-277GHR at a 
similar size, it is unlikely that the 75kDa band detected above was an isoform previously 















Immunoblotting with the B12 antibody once again detected the 110kDa and 72kDa bands 
following GHR overexpression (Kyse 150+GHR lane) (Fig.14B). Neither of these two bands 
were seen in any other of the cell lines, although, this may be a result of the uneven protein 
loading between lanes as evidenced by β-Tubulin immunoblotting (Fig.14B). Even with the 
uneven loading, a 95kDa band was seen in all cell lines tested (Fig.14B). Another study 
convincingly showed that using the same antibody, the 95kDa band was deemed to be GHR 
(Arturi et al., 2011), despite the band’s size being far below the 120-130kDa size other 
studies showed to be GHR (Asa et al., 2007; Kerkhof et al., 2007; Ross et al., 1997; Stubbart 
et al., 1991; Wang et al., 1992). The same study did not indicate whether the 95kDa band 
was mature, full-length GHR, an isoform, or a precursor of GHR. Regardless of T47D having 
been reported to express GHR at 120kDa (Xu et al., 2011), this was not seen here using 
either of the GHR antibodies, possibly indicating a low sensitivity of these antibodies that are 























Given the possible insensitivity of the GHR antibodies, it was thought that 30µg of crude 
protein lysate may be insufficient to detect the 110kDa GHR band. 100µg of crude protein 
lysate was then immunoblotted with both GHR antibodies (Fig.15). 
 
Figure 15: GHR expression in OSSC cell lines and fibroblast cells. 100µg of crude protein lysate from cell lines indicated was 
analysed by immunoblotting with the two GHR antibodies as described in materials and methods. Only 15µg lysate from 
the overexpressing cell line (Kyse 150+GHR) was used. The same nitrocellulose membrane was probed with the Mab 263 
antibody, stripped, and then probed with the B12antibody. β-Tubulin was included as a control for protein loading. Sizes of 
bands are indicated. (A) Immunoblotting with the GHR antibody Mab 263. (B) Immunoblotting with the GHR antibody B12. 
 
Once again, when probing with the Mab 263 antibody, a faint 110kDa band was observed 
following overexpression (Kyse 150+GHR lane), better visible at longer exposures (data not 
shown). A 75kDa band was seen in a majority of cell lines (Fig.15, top panel). However, 
despite uneven loading, a faint 110kDa band was seen in WHCO1, WHCO5, WHCO6, Kyse 30, 
and Kyse 150, indicating possible GHR protein expression in these cell lines (Fig.15, top 
panel). This would not, however, follow the expression profile of GHR mRNA as the Kyse 150 
cell line had previously been shown not to express detectable GHR mRNA (Fig.12). The 
expression profile of the 75kDa band does not follow that observed in Fig.14, possibly due to 
incomplete solubilisation of membrane proteins in an effort to obtain a high concentration 












Stripping and reprobing of the same nitrocellulose membrane with the B12 GHR antibody 
once again revealed the detection a 110kDa and a 72kDa band following GHR 
overexpression (Kyse 150+GHR lane), and a 95kDa band in all cell lines tested (Fig.15, middle 
panel). However, with the increased loading of protein, a 120kDa band was now detected in 
T47D and Kyse 180 cells (Fig.15, middle panel), following the mRNA expression profile since 
these two cell lines have been shown to express the highest levels of GHR mRNA (Fig.12). 
Since the size of this band would be consistent with previous studies that detected mature 
GHR at 120kDa, it would suggest possible expression of mature GHR protein in these two cell 
lines. The inability to detect either the 110kDa or 120kDa band in other cell lines despite 
showing mRNA expression in the majority in these cell lines could reflect the possible 
insensitivity of these GHR antibodies and/or the low levels of the mature GHR protein in 
these cells. Regardless of the possibility of incomplete solubilisation of membrane proteins, 
the 95kDa band was once again seen as before (Fig.14B), indicating that this band is likely a 
cytosolic protein. Additionally, when probing higher amounts of crude lysate, it was revealed 
that the intracellular domain of GHR (detected at 72kDa) was present in WHCO1, WHCO5, 
WHCO6, Kyse 30, Kyse 180, and Kyse 450 cells. 
2.2.3 GHR Localisation by Immunocytochemistry 
The inability to detect endogenous levels of GHR in denaturing gels could be due to the need 
of GHR to be in its native, non-denatured state to be detected by these GHR antibodies, 
although this is not discussed in the literature. To test this, GHR expression was investigated 
by immunocytochemistry. Additionally, as mentioned previously, several studies suggest a 
possible role of nuclear-localised GHR as a mechanism for tumourigenesis. 
Immunocytochemistry was employed to investigate the subcellular localisation of GHR in 


















antibodies), secondary antibody only (2
o
 antibody only), and DAPI only. MCF7 and Kyse 150+GHR cells were tested for GHR 
detection by means of immunocytochemistry (top and middle panels respectively). Differing protocols for fixation, blocking, 
and antibody incubation, as described in materials and methods, gave similar results as above. To investigate for normal 
levels of signal with functioning antibodies, HepG2 cells were processed in the same manner as the cell lines used for GHR 
detection except that PGM1 was detected for (lower panel). (B) Western blot analysis indicating that the Kyse 150+GHR 

















Firstly, to investigate whether the system is functional, GHR immunocytochemistry was 
conducted on the human breast cancer cell line, MCF 7; a cell line previously shown to 
exhibit detectable levels of nuclear-localised GHR (Lincoln et al., 1998) (Fig.16A, top panel). 
The Mab 263 antibody was used since it had been previously used to investigate the 
localisation of GHR (Gebre-medhin et al., 2001; Lincoln et al., 1999). Incubation with 1o and 
2o antibodies resulted in a low intensity signal (Fig.16A, top panel), that was similar in signal 
strength when incubating with 2o antibody only. No signal was observed when neither 1o nor 
2o antibody was used, other than the nuclear DAPI signal (Fig.16A, top panel). This indicated 
that signal seen when incubating with 1o and 2o antibodies was likely due to the non-specific 
binding of the 2o antibody (as evidenced by incubation with 2o only), rather than localisation 
of GHR. Using differing fixing, blocking, and incubation conditions as described in materials 
and methods gave similar results. 
Conducting immunocytochemistry on Kyse 150 cells transiently verexpressing GHR (Kyse 
150+GHR) gave similar results as above (Fig.16A, middle panel). Additionally, using the 
differing fixing, blocking, and incubation conditions as described in materials and methods 
also gave similar results. Kyse 150 cell were shown to be successfully overexpressing GHR as 
evidenced by immunoblotting with the B12 GHR antibody (Fig.16B).  
To test whether the lack of signal was a reflection of a general technical problem, or 
confined to GHR detection, the human hepatoma cell line, HepG2, were used to detect for 
phosphoglucomutase 1 (PGM1) localisation. Our laboratory has previously demonstrated 
that PGM1 is normally localised in the cytosol (unpublished data), as observed when 
incubated with 1o and 2o antibody (Fig.16A, bottom panel). Furthermore, the signal is 
significantly weaker when incubating with 2o only, indicating that the high signal when 
incubating with 1o and 2o antibodies is due to the specific binding of the 1o antibody to its 
epitopes present on PGM1. HepG2 cells were prepared in the same manner as for GHR 
detection, indicating that the system allowed for efficient fixing, binding of antibody, and 
detection of signal. These results suggest the possible insensitivity of these GHR antibodies, 
particularly the antibody used for GHR immunocytochemistry, Mab 263. Additionally, a high 














2.3 Characterisation of the GHR Protein Bands 
2.3.1 Investigation of Protein Glycosylation 
One of the many post-translational modifications proteins are subjected to before becoming 
mature, functional proteins is glycosylation. Glycosylation serves a wide spectrum of 
purposes, including the maintenance of the structural integrity of the protein (Varki et al., 
2009). Glycosylation is the process of attaching glycan chains to specific sites within the 
protein (Varki et al., 2009). Several classes of glycans exist, the most common being N-linked 
glycans that are attached to specific asparagine side-chains within the protein (Varki et al., 
2009).  
It has been previously shown that mature GHR is N-link glycosylated, a d that removal of 
these glycan chains by means of digestion with specific amidases resulted in a significant 
increase in GHR motility through SDS-PAGE gels (Asa et al., 2007). To investigate whether 
the 95kDa and 75kDa bands detected with the B12 and Mab 263 GHR respectively are either 
isoforms or precursor GHR proteins, Kyse 150 cells overexpressing GHR were treated with 
tunicamycin (Fig.16), an antibiotic known to inhibit several enzymes that catalyse the first 
steps of N-linked glycoprotein synthesis (Heifetz et al., 1978). This would also serve to 














Figure 17: Tunicamycin treatment of GHR overexpressing Kyse 150 cells. Kyse 150 cells were induced to transiently 
overexpress GHR by means of transfection. The overexpressing cells were then treated with tunicamycin (0.05µM and 1µM) 
for 24hrs, as described in materials and methods. β-Tubulin was included as a control for protein loading. Sizes of bands are 
indicated. Depicted results are representative of two separate experiments.(A) Immunoblotting with the B12 antibody. (B) 


















As previously observed (Fig.13A, 14B, 16B), overexpression of GHR was associated with the 
expression of the 110kDa and 72kDa bands when immunoblotted with the B12 GHR 
antibody (Fig.17A). Treatment with increasing concentrations of tunicamycin resulted in 
decreased levels of the 110kDa while the 95kDa band increased in intensity (Fig.17A). The 
95kDa band was also observed in untransfected cells (Kyse 150 lane) at longer exposures 
(not shown). There was no increase in the introduced 72kDa band. These results suggest 
that the 110kDa and 95kDa bands detected with the B12 antibody could possible correlate 
to fully-glycosylated GHR, and unglycosylated, precursor GHR respectively. The 72kDaband 
observed after GHR transfection and its unresponsiveness to tunicamycin treatment could 
indicate that the intracellular domain of GHR is unglycosylated, which is to be expected as 
only extracellular domains are glycosylated. The low levels of the unglycosylated, precursor 
form of GHR following inhibition of glycosylation compared to the high levels of glycosylated 
GHR when overexpressed indicate that the precursor form may have a short half-life, shorter 
than the 24hrs of tunicamycin treatment. However, this may be highly unlikely given since 
preventing glycosylation may also affect transcription and/or translation machinery. 
Similar results were found when immunoblotting with the Mab 263 antibody (Fig.17B). Once 
again, the 110kDa band decreased with tunicamycin treatment. However, a 95kDa band, 
previously not seen when detecting with this antibody, increased in intensity in response to 
treatment with tunicamycin (Fig.17B). Given that the blot was probed with B12 and stripped 
prior to reprobing with the Mab 263 antibody, and given that the 72kDa band is seen when 
probing with Mab 263 (a band not previously seen when immunoblotting with Mab 263), 
incomplete stripping of the membrane prior to reprobing with Mab 263 may not be 
excluded. However, the 75kDa failed to respond to tunicamycin treatment, indicating that it 
was unlikely to be a GHR isoform as one would expect it to be glycosylated, or a precursor, 
unglycosylated form of GHR, as it did not increase in intensity following inhibition of 
glycosylation. Given that GH binds to PRLR, and that Mab 263 binds within the binding 
region for GH, it could be possible that the Mab 263 antibody could detect PRLR. However, 
the 75kDa band does not correlate to any size of known PRLR isoforms (Gadd and Clevenger, 
2006), thus inferring that the 75kDa band is unlikely PRLR. These results indicated that the 












In agreement with the results described above, when immunoblotting with the HA antibody, 
the 110kDa band observed following GHR overexpression once again decreased in intensity 
with increasing concentrations of tunicamycin (Fig.17C). A 95kDa band was observed 
following treatment with tunicamycin, a band not previously observed when 
immunoblotting with this antibody (Fig.16C). These results suggest that the 110kDa band 
observed following GHR overexpression is likely to be mature, full-glycosylated GHR, while 
the 95kDa band observed following treatment with tunicamycin is likely to be 
unglycosylated, precursor GHR. This further could imply that the 95kDa band observed in all 
cell lines when immunoblotting with the B12 antibody may well be a precursor form of GHR. 
Since protein loading was even, the different intensities of the different bands were not 
attributed to protein loading. It should be mentioned that the 95kDa band is still significantly 
larger than the predicted 72kDa size of GHR based on its amino acid sequence. This could be 
as a result of other possible post-translational modifications GHR is subjected to such as O-
linked glycosylation or ubiquitination, or may reflect formation of protein complexes 























2.3.2 GHR Knockdown 
To confirm whether the 95kDa band observed, specifically when immunoblotting with the 
B12 antibody, was related to GHR, GHR was knocked down in the Kyse 180 cell line using 
commercially available small interfering RNA (siRNA) (Fig.18). The siRNA binds to exon 5 of 
GHR mRNA, and should therefore knock down flGHR along with all other known isoforms of 
GHR. 
 
Figure 18: GHR knockdown in characterising the 95kDa band. Kyse 180 cells were transfected with 20nM, 40nM, and 
60nM GHR and control siRNA as described in materials and methods. Protein and RNA was then isolated 24hrs post-
transfection. β-Tubulin was included as a control for protein loading. Sizes of bands are indicated. Depicted results are 
representative of two separate experiments. (A) Immunoblotting of cell lysates with the B12 GHR antibody. Densitometry 













As evidenced by immunoblotting with the B12 antibody, transfection with increasing 
concentrations of GHR siRNA failed to induce a decrease in the 95kDa band that was visible 
to the eye (Fig.18A). However, densitometry analysis performed on the 95kDa band at the 
differing siRNA concentrations showed an average 15% decrease when normalising to β-
Tubulin, indicating a possible link between the 95kDa band and GHR. GHR qRT-PCR analysis 
on mRNA isolated at the same time point as for protein isolation indicates that GHR mRNA 
was knocked down, with an approximately 50% decrease in total GHR mRNA transcripts 
levels irrespective of the concentration of siRNA used (Fig.18B). This decrease in GHR mRNA, 
however, did not translate in a 50% decrease in the 95kDa band. These findings suggest that 
while the 95kDa band may be a form of GHR, its protein knockdown does not correlate to 
mRNA knockdown. This could be indicative of a non-specific protein band also detected by 
the B12 antibody at 95kDa.Alternatively, the inefficient and short knockdown of GHR mRNA 
could explain the relatively insignificant decrease in the 95kDa band. It is possible that, if the 
95kDa band does represent unglycosylated GHR, a greater decrease in the intensity of the 
band would have been observed at longer time points following transfection of siRNA, as 
protein lysates were harvested 24 hours after transfection. Unfortunately this could not be 





















2.3.3 GHR Expression following Serum Starvation 
There is evidence that serum starvation may increase the expression levels of GHR protein, 
specifically in the T47D cell line (Xu et al., 2011). It is possible that expression levels of GHR 
are too low for the immunoblotting detection system, and serum starvation could increase 
levels of GHR protein expression by reducing the rate of internalisation. To identify 
endogenously expressed GHR, T47D cells were subjected to serum starvation, SDS-PAGE, 
and immunoblotting with the B12 antibody (Fig.19). 
 
Figure 19: GHR expression in response to serum starvation. T47D cells were subjected to serum starvation for the times 
indicated, protein isolated, electrophoresed, and immunoblotted with the B12 antibody as described in materials and 
methods. β-Tubulin was included as a control for protein loading. Sizes of bands are indicated. Depicted results are 















Transfection of the GHR expression plasmid in Kyse 150 cells (Kyse 150+GHR) once again 
resulted in the detection of the 110kDa and 72kDa bands. Immunoblotting with the B12 
antibody revealed 120kDa and 95kDa bands in T47D cells regardless of serum starvation 
(Lane 1, Fig.19). There was no visible increase in intensity of the 95kDa band in response to 
serum starvation (Fig.19). Interestingly, the 120kDa showed a slight increase in expression 
levels following serum starvation at 24hrs and 48hrs (Fig.19). A 110kDa seemed to be 
induced following 48hrs of serum-starvation, however, as evidenced by the presence of the 
110kDa band in the untreated T47D lane (Lane 7), since this band had previously seen no to 
be expressed by T47D (Lane 1), the introduction of the band may likely be due to overflow of 
protein while loading the positive control (Lane 6), or signal bleed-through from the adjacent 
lane, rather than in response to serum starvation (Fig.19). This is supported by other serum-
starving experiments which similarly failed to induce the 110kDa band (data not shown). 
2.3.4 Immunoprecipitation of GHR 
To finally deduce whether endogenous levels of GHR may be detected using these two 
antibodies, and whether endogenous GHR is detectable at 110kDa or 120kDa, 1mg of crude 
protein lysate isolated from T47D cells. As a control for the immunoprecipitation, 100µg of 
protein isolated from GHR-overexpressing and untransfected Kyse 150 cells, was subjected 
to immunoprecipitation by the Mab 263 antibody, and immunoblotted with the B12 
antibody (Fig.20). Immunoprecipitation was done on 100µg of lysate rather than the 1mg 
used for immunoprecipitation for T47D protein in an effort to save reagents, and because it 
was suspected that 100µg of lysate from GHR-overexpressing cells would contain sufficient 













Figure 20: Immunoprecipitation of GHR: GHR was immunoprecipitated fromT47D, transiently overexpressing Kyse 150 
(Kyse 150+GHR), and untransfected Kyse 150 cells as described in materials and methods. Immunpreciptiations were 
performed on 1mg T47D, 100µg Kyse 150+GHR, and 100µg Kyse 150 crude protein. The same amount of crude lysate 
incubated with protein beads only was also included as a control for non-specific protein binding to beads. 10% input of 
crude lysate used for immunoprecipitation was included. 
 
The expected 110kDa and 72kDa bands were observed when overexpressing GHR by means 
of transfection with the GHR xpression plasmid (Kyse 150+GHR Input lane) (Fig.20). Both 
bands could be immunoprecipitated (Fig.20). The 95kDa band seen in untransfected cells 
could not be immunoprecipitated, probably due to the low amount of starting crude protein 
material from which the immunoprecipitation was performed (Fig.20). The detection of the 
110kDa with the B12 antibody following immunoprecipitation with the Mab 263 antibody 
further confirms the 110kDa band is most likely GHR in cells transfected with the GHR 
expression plasmid. Immunoprecipitation of the 72kDa band from lysate of GHR transfected 
cells is not consistent with the assumption that this band represents the ICD remnant 
following cleavage of the ECD, since the immune precipitating antibody (Mab263) does not 
recognize the intracellular domain of GHR. However, the ratio of the band intensities in the 
input and immunoprecipitation indicates that, of the 72kDa protein present in the starting 












possible that the presence of this band in the immunoprecipitate Is indicative of a low level 
of protein cleavage or degradation during the immunoprecipitation experiment.(Fig.17). 
Immunoprecipitation of crude lysates isolated from T47D cells show two bands being 
successfully pull down, at 120kDa and 95kDa (Fig.20). The same 120kDa and 95kDa bands 
are also seen when immunoblotting the input lysate prior to immunoprecipitation (Fig.20).  
Since non-specific binding to the sepharose matrix may be ruled out, as evidenced by the 
lack of protein bands observed when incubating crude lysate with protein G-sepharose 
beads only (Fig.20), these results confirm that the 110kDa band observed following GHR 
overexpression is GHR. Additionally, the 120kDa band seen here to be immunoprecipitated, 
was observed to increase in expression in response to serum starvation (Fig.19), confirming 
its possible identity as GHR. Interestingly, the successful immunoprecipitation of a 95kDa 
band, only visible when overexposing the film and immunoprecipitating from large amounts 
of crude protein lysates, could also be viewed as evidence for its possible identity as a form 






















2.3.5 Bioactivity Assay 
Since the results suggest that the 120kDa and 110kDa bands may be GHR, phosphorylation 
of these two bands in response to GH stimulation was investigated (Fig.21). Protein lysates 
from Kyse 180 cells were also included. Since Kyse 180 cells exhibited highest expression of 
GHR mRNA in all OSCC cell lines tested, it was thought that it may serve as the best 















Figure 21: Protein band phosphorylation in response to 500ng/ml GH stimulation. Sizes of bands are indicated. 
Stimulation was performed when cells reached 70% confluency. (A) Following serum starvation for 24hrs, 1mg of T47D and 
Kyse 180 protein, either treated with GH or without for 5min, was immunoprecipitated with the Mab 263 antibody as 
described in materials and methods. The same was done on 100µg GHR overexpressing cells (Kyse 150+GHR). Following 
SDS-PAGE electrophoresis, the PDVF membrane was immunoblotted for phosphorylated tyrosine (pTyr) (top panel). The 
membrane was then stripped, and reprobed for GHR with the B12 antibody (middle and lower panels). (B) 10% input for 
the immunoprecipitations were probed with the B12 antibody. β-Tubulin was included as a control for assessing equal 
amounts of protein used per immunoprecipitation in the three separate cell lines. (C) Protein lysates isolated from WHCO1 
treated with or without EGF (20ng/ml) was used as a control for testing the sensitivity of the phosphorylated tyrosine 
antibody. 300µg of protein was immunoprecipitated using an EGFR antibody, and phosphorylated tyrosine was detected 













Immunoblotting for phosphorylated tyrosines following GHR immunoprecipitation revealed 
several bands. Firstly, a 95kDa band was immunoprecipitated in all cells tested (Fig.21A, top 
panel). Faint 110kDa and 120kDa bands were also immunoprecipitated from T47D and Kyse 
180 cells tested (Fig.21A, top panel). In addition, two other bands of 130kDa and 80kDa were 
immunoprecipitated from Kyse 180 cells (Fig.21A, top panel).The 130kDa band could 
possibly correspond to phosphorylated JAK2, consistent with previous reports (Yin et al., 
1994), while the 80kDa band may correspond to one of the many transcription factors, 
kinases, and adaptor proteins known to associate with GHR upon activation by GH 
respectively. Ideally, to confirm the 130kDa band as phosphorylated Jak2, the membrane 
should have been probed with a Jak2 antibody, however, since the experiment was done 
late on in the project, this was unfeasible. None of the bands immunoprecipitated from 
T47D cells exhibited increased phosphorylation in response to GH treatment (Fig.21A, top 
panel), whereas the 80kDa, 120kDa, and 130kDa showed increased phosphorylation in 
response to GH treatment in Kyse 180 cells (Fig.21A, top panel). GHR overexpressing cells 
(Kyse 150+GHR) only revealed a 95kDa band when immunoblotting for phosphorylated 
tyrosine, which exhibited no increase in phosphorylation in response to GH treatment. 
Immunoblotting the same membrane for GHR with the B12 antibody following stripping 
revealed the same bands in T47D and Kyse 180 when overexposing the film (Fig.21A, lower 
panel). GHR overexpressing Kyse 150 cells exhibited 110kDa and 80kDa bands when 
immunoblotting with the B12 antibody (Fig.21A, middle and lower panel). 
Immunoblotting 10% inputs used for immunoprecipitations for GHR with the B12 antibody 
revealed 95kDa bands being detected in all three cell lines (as previously seen in Fig.14B), 
with the addition of 120kDa bands being observed in T47D and Kyse 180 cells, with the 
former showing smudging of the 120kDa band (Fig.21B, middle panel). GHR overexpressing 
cells also exhibited the expected 110kDa and 72kDa bands (Fig.21B, top panel). β-Tubulin 
immunodetection was then performed on the same PVDF membrane following stripping, 















Since our laboratory has previously observed the phosphorylation of epidermal growth 
factor receptor (EGFR) in response to epidermal growth factor (EGF) stimulation in WHCO1 
cells (unpublished data), protein isolated from WHCO1 cells treated with or without EGF was 
also immunoprecipitated to test for the activity of the phosphotyrosine antibody (Fig.21C). 
Epidermal growth factor receptor (EGFR) was immunoprecipitated and tested for 
phosphorylation in response to EGF stimulation using the same phosphotyrosine antibody as 
above. The same blot was then stripped and reprobed for total EGFR (Fig.21C, middle and 
lower panels). A 170kDa band corresponding to EGFR was immunoprecipitated, and showed 
a high level of phosphorylation of tyrosine residues in response to EGF stimulation (Fig.21C, 
top panel), indicating that the system used for detecting phosphorylated tyrosine was 
functional. Difference in level of total EGFR protein being immunoprecipitated between the 
sample treated with EGF and the sample treated without EGF could be as a result of 
receptor internalisation and degradation in response to EGF binding rather than uneven 
amounts of protein used for the immunoprecipitation (Fig.21C, middle and lower panel). 
These findings suggest that in Kyse 180, since the 130kDa, 120kDa, 110kDa, and 80kDa 
exhibited increased phosphorylation in response to GH stimulation, and since all these bands 
were able to be detected when immunoblotting with the B12 antibody, that these four 
bands may be variants of GHR and/or proteins associated with GHR in the presence of GH 
(Fig.21A). Given that endogenous GHR was possibly detected at 120kDa, similar levels of the 
band was not present in the samples not treated with GH compared to GH-treated samples 
when detecting GHR (Fig.21A, lower panel).It is possible that unequal amounts of protein 
were immunoprecipitated, but that seems unlikely considering that β-Tubulin levels in 10% 
protein input indicated that starting crude protein material was for within these two 
samples (Fig.21B, lower panel), however, as evidenced by the slight decrease in the Fc 
fragment between the two sample, amounts of immunoprecipitating antibody used may not 
be equal, with the sample being treated without GH receiving less Mab 263 than the sample 
treated with GH (Fig.21A, top panel). Since the same protein bands were seen when 
immunoblotting for phosphorylated tyrosine residues and GHR, it could also be argued that 
stripping of the membrane failed to effectively strip previously bound antibodies. It should 
be noted that given that the experiment was conducted late on in the project, the 
experiment was unable to be reproduced. Despite the uncertainty regarding the bands 












band seen following GHR overexpression does not respond to GH treatment, with none of 
the bands immunoprecipitated in T47D cells also showing no response to GH treatment. 
The lack of tyrosine phosphorylation in response to GH stimulation of T47D cells was 
particularly concerning, since T47D cells have been reported to respond to the same 
concentration of GH (500ng/ml) by phosphorylating STAT5, and this response was shown to 
be largely mediated by GHR, and to a lesser extent by PRLR, thus inferring the presence of 
functional GHR proteins within T47D cells (Xu et al., 2011). The above results would also be 
observed if the GH used in the treatment was ineffective. To test for GH activity, the same 
crude protein lysates used above underwent immunoblotting for phosphorylation of ERK1/2, 
a known downstream target of GH signalling (Fig.22).Our laboratory has previously observed 
that treatment with EGF induces ERK1/2 phosphorylation (pERK1/2) in WHCO1 cells 
(unpublished data), and this was therefore included as a positive control for the pERK1/2 
antibody (Fig.22B).   
 
Figure 22: ERK1/2 phosphorylation in response to ligand. 30µg of crude protein lysates used in Fig.21 underwent 
immunoblotting for phosphorylated ERK1/2 (pERK1/2) as described in materials and methods. β-Tubulin was included as a 
control for protein loading. Sizes of bands are indicated. Results are representative of two separate experiments. Depicted 
results are representative of two separate experiments. (A) pERK1/2 in response to GH treatment (500ng/ml) for 5min in 

















Following immunoblotting for phosphorylated ERK1/2, two bands were observed at 44kDa 
and 42kDa in size, corresponding to ERK1 and ERK2 respectively (Fig.22). In Kyse 180 cells, 
GH treatment induced significant phosphorylation of ERK1/2, indicating that GH was 
functional (Fig.22A), either acting through GHR, PRLR, or both to induce this response. Oddly 
though, GH failed to induce any phosphorylation of ERK1/2 above that of basal levels in 
T47D cells (Fig.22A). This was unexpected since T47D cells have been demonstrated to 
express functional GHR and PRLR protein, both of which respond to GH treatment by 
activating STAT5 (Xu et al., 2011). Given the unexpected non-responsiveness of T47D cells to 
endogenous GH, cells lines would have to be verified by DNA fingerprinting or otherwise. 
When treating WHCO1 cells with EGF, a significant pERK1/2 response was observed 
(Fig.22B), indicating that the pERK1/2 antibody and the system of detection was functional. 
Since immunodetection for β-Tubulin revealed even protein loading, these results suggest 
that GH was functional, and did induce the phosphorylation of ERK1/2 in Kyse 180 cells. The 
lack of induction in T47D cells, a cell line previously shown to express functional GHR and 
PRLR proteins, indicated that in our T47D cells, GHR and PRLR may be dysfunctional. 
Furthermore, the possibility exists that the T47D cells in our laboratory could be 
contaminated with another cell line. Additionally, differences in culture conditions and/or 
experimental conditions could also account for differences between results observed here 























EFFECT OF GHR KNOCKDOWN ON CANCER CELL BIOLOGY 
 
3.1 Effect of GHR Knockdown on Proliferation and IC50 in Kyse 180 
As stated before, GH has been shown to exert tumourigenic effects in a number of studies 
using variousin vitro and in vivo models. Additionally, it was found that the effects of GH 
were largely mediated by GHR in the few studies that investigated possible mechanisms 
whereby GH may exert its tumourigenic effects. GH mRNA has been shown to be expressed 
in the majority of OSCC cell lines tested, indicating a possible role for the GH axis in 
tumourigenesis in these cell lines. In keeping with the literature, since GHR mRNA expression 
has also been shown, it is possible that the potential tumourigenic effectsof GH may be 
directly mediated by GHR. To investigate this GHR was knocked down in Kyse 180 cells, a cell 
line shown to express GH and GHR mRNA, by means of siRNA transfection. Proliferation 
(Fig.23) and response to chemotherapeutic agents (Fig.24) following GHR knockdown were 
measured. This served to investigate the role of GHR in regulating proliferation and response 





















Figure 23: Proliferation in response to GHR knockdown in Kyse 180 cells. Kyse 180 cells underwent transfection with 20nM 
siRNA as described in materials and methods. A proliferation assay was used to measure cell proliferation and RNA was 
isolated and analysed for GHR expression by means of GHR PCR following cDNA conversion, as described in materials and 
methods. (A) Proliferation of cells transfected with either GHR or controls siRNA. The results are representative of three 
independent experiments. (B) Difference in proliferation at 96hrs post-transfection (n=3, *=p<0.05). Data was normalised 
to the initial plating at the start of the proliferation assays, and to control siRNA knockdown within the three separate 
experiments. (C) Quantification of GHR mRNA levels relative to control siRNA at 24hrs and 96hrs post-transfection. Pooled 













Following GHR knockdown, there was a 18% decrease in proliferation at 96hrs post-
transfection compared to control siRNA transfected cells (Fig.23A&B). This decrease has 
been shown to be statistically significant (Fig.23B). The decrease in proliferation was 
accompanied by a statistically significant 50% decrease in GHR mRNA at 24hrs and 96hrs 
(Fig23.C). Sensitivity to chemotherapeutic agents in response to GHR knockdown was also 
measured. This was done by determining the IC50 values, the concentration needed to inhibit 
proliferation by 50%, of the drugs cisplatin and doxorubicin (Fig.23). Furthermore, treatment 
with a combination of different GHR siRNA sequences or transfection using a lentiviral 
















Figure 24: Effect of GHR knockdown on response to cisplatin and doxorubicin in Kyse 180 cells. Kyse 180 cells were 
transfected with siRNA, and treated with a range of concentrations of cisplatin and doxorubicin, as described in materials 
and methods. RNA was isolated 24hrs post-transfection, and at the end time-point of the drug treatment assays (96hrs 
post-transfection) as described in materials and methods. (A) Pooled dose response curves for cisplatin and doxorubicin 
following GHR (•) and control (  ) knockdown (n=3). (B) Pooled quantification of IC50 values for cisplatin and doxorubicin 
following GHR and control knockdown. 95% confidence intervals (95% CI) are also shown (n=3). (C) Quantification and 
normalisation of GHR mRNA to control knockdown at 24hrs and 96hrs post-transfection for the three separate experiments 
















Knockdown of GHR failed to induce a visible shift in IC50 graphs for both cisplatin and 
doxorubicin, indicating that there was no difference in sensitivity to chemotherapy following 
GHR knockdown compared to control knockdown(Fig.24A). This was further confirmed by 
quantified IC50 values. Although a 7% decrease in IC50was observed for both cisplatin and 
doxorubicin following GHR knockdown, this difference was not statistically significant as 95% 
confidence intervals are observed to overlap for both GHR and control knockdown (Fig.24B). 
These results were accompanied by a statistically significant 50% knockdown of GHR mRNA 
(Fig.24C). 
These results suggest that GHR plays a small role in proliferation, while not affecting the 
response of cells to cisplatin and doxorubicin. The decrease in proliferation was small but 
significant, with only a 18% decrease in proliferation observed following GHR knockdown, at 
96hrs post-transfection. The lack of decrease in IC50 values following GHR knockdown seems 
to be contrary to the literature that shows a protective function of autocrine GH, one that is 
mediated by GHR (Minoia et al., 2012; Zatelli et al., 2009). This indicates that while there 
may be a role of autocrine GH in Kyse 180 cells, as evidenced by the endogenous expression 
of GH mRNA, these cells seem to be relatively uninfluenced by the disruption of autocrine 
GH signalling by knocking down GHR. Finally, since these results were observed with only a 
50% knockdown of GHR mRNA, it may be argued that the small effect observed on 
proliferation is a result of the inefficient knockdown of GHR, thereby maintaining the 
possibility that these cells may be dependent on the intact signalling of autocrine GH 
through GHR. To further validate the effects of GHR on proliferation in OSCC, GHR 
knockdown in other OSCC cell lines was investigated. 
Addition of exogenous GH to cells that underwent GHR knockdown could have exaggerated 
the proliferative effect and shown a potential chemoprotective effect of GH, however, when 
treating cells with exogenous GH, an increase in proliferation was not seen in Kyse 180 cells 
(data not shown). These results indicate that in Kyse 180 cells, autocrine GH is sufficient to 
saturate GHR signalling, so that addition of additional exogenous GH does not result in 
increased efficacy. Although this was only demonstrated in proliferation assays, we 














3.2 Effect of GHR Knockdown on Proliferation and IC50 in Kyse 30 
GHR knockdown effects on proliferation and IC50 concentrations of cisplatin and doxorubicin 
was also performed on the Kyse 30 cell line (Fig.25 and Fig.26 respectively). The Kyse 30 cell 
line was selected to elucidate the role of the d3GHR isoform on proliferation and response 
to chemotherapeutic drugs. 
 
Figure 25: Proliferation in response to GHR knockdown in Kyse 30 cells. Kyse 30 cells underwent transfection with 20nM 
siRNA as described in materials and methods. A proliferation assay was used to measure cell proliferation and RNA was 
isolated and analysed for GHR expression by means of GHR PCR following cDNA conversion, as described in materials and 
methods. (A) Proliferation of cells transfected with either GHR or controls siRNA. The results are representative of three 
independent experiments. (B) Difference in proliferation at 96hrs post-transfection (n=3). Data was normalised to the initial 
plating at the start of the proliferation assays, and to control siRNA knockdown within the three separate experiments. (C) 
Quantification of GHR mRNA levels relative to control siRNA at 24hrs and 96hrs post-transfection. Pooled results of three 












Kyse 30 cells have previously been shown to express only d3GHR mRNA (Fig.12). GHR 
knockdown inhibited proliferation to a small extent (Fig.25A). However, the decrease in 
proliferation was not deemed significant when normalised to initial plating densities over 
the three separate experiments conducted (Fig.25B), despite achieving a 70% knockdown of 
GHR mRNA in these three experiments (Fig.25C). Concurrently to the proliferation assays, 
drug treatments assays for cisplatin and doxorubicin were also performed (Fig.26). 
 
Figure 26: Effect of GHR knockdown on response to cisplatin and doxorubicin in Kyse 30 cells. Kyse 30 cells were 
transfected with siRNA, and treated with a range of concentrations of cisplatin and doxorubicin, as described in materials 
and methods. RNA was isolated 24hrs post-transfection, and at the end time-point of the drug treatment assays (96hrs 
post-transfection) as described in materials and methods. (A) Pooled dose response curves for cisplatin and doxorubicin 
following GHR (•) and control (  ) knockdown (n=3). (B) Pooled quantification of IC50 values for cisplatin and doxorubicin 
following GHR and control knockdown. 95% confidence intervals (95% CI) are also shown (n=3). (C) Quantification and 
normalisation of GHR mRNA to control knockdown at 24hrs and 96hrs post-transfection for the three separate experiments 












There was no shift in IC50 curves for both cisplatin and doxorubicin, indicating no change in 
IC50values following GHR knockdown compared to control knockdown (Fig.26A). This was 
confirmed by the overlapping 95% CI intervals for both drugs and overlapping IC50 values for 
doxorubicin, despite observing a 12% decrease in IC50 concentration for cisplatin following 
GHR knockdown (Fig.26B). These results were observed despite a 70% decrease in GHR 
mRNA levels (Fig.26C), as calculated following qRT-PCR with the flGHR gene-specific primers 
that also bind d3GHR cDNA. Since K30 has been shown to express d3GHR exclusively, the 
70% knockdown seen following flGHR qRT-PCR thus correlates to a 70% decrease in d3GHR 
mRNA. The d3GHR primers could not be used for qRT-PCR since it is able to amplify and 
distinguish two products, flGHR and d3GHR. 
Since knocking down d3GHR failed to induce any change in proliferation or IC50 
concentrations of both cisplatin and doxorubicin, it can be inferred that Kyse 30 cells do not 
rely on d3GHR for proliferation, and knockdown does not potentiate the effects of cisplatin 
and doxorubicin. It can be further inferred that, since these experiments were conducted in 
10% foetal bovine serum and is therefore likely to be exposed to levels of GH, the GH/IGF1 
axis possibly does not play a role in proliferation or chemoresistance in the Kyse 30 cell line. 
Possible explanations could include the translation of dysfunctional d3GHR or lack of mRNA 
translation. Additionally, the relatively inefficient knockdown of GHR may not be ignored it is 
possible that a change in proliferation and/or chemosensitivity would have been seen if a 





















3.3 Effect of GHR Knockdown on Proliferation and IC50 in Kyse 450 
GHR knockdown effects on proliferation and IC50 concentrations of cisplatin and doxorubicin 
was also performed on the Kyse 450 cell line (Fig.27 and Fig.28 respectively), a cell line 
similar to Kyse 180 in that Kyse 450 cells likely express flGHR mRNA predominantly, with no 
expression of d3GHR (Fig.12). However, as with Kyse 180, possible 1-279 and 1-277GHR 
isoforms within Kyse 450 cells may not be ignored. 
 
Figure 27: Proliferation in response to GHR knockdown in Kyse 450 cells. Kyse 450 cells underwent transfection with 20nM 
siRNA as described in materials and methods. A proliferation assay was used to measure cell proliferation and RNA was 
isolated and analysed for GHR expression by means of GHR PCR following cDNA conversion, as described in materials and 
methods. (A) Proliferation of cells transfected with either GHR or controls siRNA. The results are representative of three 
independent experiments. (B) Difference in proliferation at 96hrs post-transfection (n=3). Data was normalised to the initial 
plating at the start of the proliferation assays, and to control siRNA knockdown within the three separate experiments. (C) 
Quantification of GHR mRNA levels relative to control siRNA at 24hrs and 96hrs post-transfection. Pooled results of three 












Unlike in the case of Kyse 180 cells, knockdown of GHR mRNA failed to induce a change in 
proliferation (Fig.27A&B). Responses to doxorubicin and cisplatin were also conduced 
concurrently to the proliferation assays (Fig.28). 
 
Figure 28: Effect of GHR knockdown on response to cisplatin and doxorubicin in Kyse 450 cells. Kyse 450 cells were 
transfected with siRNA, and treated with a range of concentrations of cisplatin and doxorubicin, as described in materials 
and methods. RNA was isolated 24hrs post-transfection, and at the end time-point of the drug treatment assays (96hrs 
post-transfection) as described in materials and methods. (A) Pooled dose response curves for cisplatin and doxorubicin 
following GHR (•) and control (  ) knockdown (n=3). (B) Pooled quantification of IC50 values for cisplatin and doxorubicin 
following GHR and control knockdown. 95% confidence intervals (95% CI) are also shown (n=3). (C) Quantification and 
normalisation of GHR mRNA to control knockdown at 24hrs and 96hrs post-transfection for the three separate experiments 















Once again, knockdown of GHR failed to induce a change in IC50 concentrations of both 
cisplatin and doxorubicin, as evidenced by the lack of shift in IC50 curves (Fig 28A), and 
overlapping of 95% CI for both drugs (Fig.28B), regardless of achieving an average 
knockdown of 60% during the course of the three separate drug treatment assays (Fig28C). 
These results suggest, as in the case of Kyse 30 cells, that GHR is not important for the 
proliferation of Kyse 450 cells, and knockdown does not potentiate the effects of cisplatin 
and doxorubicin. As in the case of Kyse 30 cells, it may also be further inferred that, since 
these experiments were conducted in 10% foetal bovine serum and is therefore likely to be 
exposed to levels of GH, the GH/IGF1 axis possibly does not play a role in the Kyse 450 cell 
line. Additionally, the translation of dysfunctional GHR may not be disproved, therefore 
explaining the above results. Also, despite Kyse 450 cells expressing GHR mRNA, this 




























3.4 ERK1/2 Phosphorylation following GHR Knockdown 
To test whether GHR is functional within the Kyse 30, Kyse 180, and Kyse 450 cell lines, 
ERK1/2 phosphorylation was investigated following GHR knockdown (Fig.29). 
 
Figure 29: ERK1/2 phosphorylation in response to GH following GHR knockdown. Kyse 30, Kyse 180, and Kyse 450 cells 
were transfected with either GHR or control siRNA (20nM), serum starved for 24hrs, and treated with GH (500ng/ml) for 
5min before protein isolation and SDS-PAGE. (A) Immunoblotting for pERK1/2.β-Tubulin was included as a control for 
protein loading. Sizes of bands are indicated. (B) Quantification and normalisation of GHR mRNA to control knockdown at 
end-time point for assay for each cell line. 
GH was able to induce ERK1/2 phosphorylation in Kyse 180 cells, but not in Kyse 30 or Kyse 
450 cells, indicating that either GHR was not functional in these cell lines, or not expressed 
at all as protein (Fig.29A). The slight increase in pERK1/2 observed in Kyse 450 cells following 
GH treatment and GHR knockdown could be as a result of uneven protein loading, as 
evidenced by immunoblotting for β-Tubulin, rather than as a response to GH (Fig 29A). 
Furthermore, since GH failed to induce phosphorylation of ERK1/2, it can be further inferred 













Once again, GH induced phosphorylation of ERK1/2 in Kyse 180 cells, however, knockdown 
of GHR failed to reduce pERK1/2. Since only 50% knockdown was achieved, inefficient 
knockdown of GHR may not be overlooked. If this is the case, 50% of original GHR levels may 
be enough to still saturate the ERK1/2 pathway in response to the high level of GH used for 
treatment in Kyse 180 cells. Alternatively, GH may be possibly acting through PRLR in order 
to achieve ERK1/2 phosphorylation. However, since PRLR expression within OSCC is beyond 
the scope of this project, the PRLR-mediated ERK1/2 phosphorylation in response to GH was 







































DISCUSSION AND CONCLUSION 
 
4.1 Discussion 
The tumourigenic effects of autocrine GH are well documented. Early studies have shown 
that administration of GH induced neoplasms in rats (Moon et al., 1950), while transgenic 
mice overexpressing human GH showed higher incidences of cancers (Törnell et al., 1992). In 
vitro studies showed that forced autocrine signalling of GH resulted in carcinogenesis in a 
number of cancer models (Brunet-Dunand et al., 2009; Kaulsay et al., 1999; Minoia et al., 
2012; Pandey et al., 2008; Segard et al., 2003; Zatelli et al., 2009). Previous studies have 
shown that the tumourigenic effects of autocrine GH are largely mediated by GHR (Goffin et 
al., 1999; Kaulsay et al., 1999; Minoia et al., 2012; Pandey et al., 2008). The objective of this 
study was to therefore determine whether GH/GHR signalling axis plays any role in the 
tumourigenic phenotype of OSCC. 
To establish whether available OSCC cell lines have established a possible GH/GHR signalling 
loop, nine OSCC cell lines were tested for GH mRNA expression. Endogenous, extra-pituitary 
expression of GH mRNA in 56% of OSCC cell lines tested reveals the possible role of GH 
signalling in OSCC (Fig.12). Of course, GH protein expression would have served as the ideal 
indicator of its potential role in OSCC, but went beyond the scope of this project. 
Furthermore, it is possible that these cells expressing endogenous GH may affect stromal 
cells by activating GH/GHR axis signalling within these cells in a paracrine manner, in 
addition to the possible role of GH autocrine signalling in OSCC. However, the experiments 
performed in this study would not expose this potential paracrine signalling of GH, and 
would require analysis of biopsy tissue. 
Another approach to determine the possible tumourigenic effects of GH signalling in OSCC 
was to investigate whether any typical tumourigenic markers of OSCC cells show 
dependency on GHR signalling. For this, GHR expression would firstly need to be 
investigated.  Given that GHR is expressed on many target tissues (Frank and Messina, 2002), 
it is unsurprising that 78% of OSCC cell lines tested expressed GHR mRNA, either that of full-












2008; Dos Santos et al., 2004) (Fig.12). Using the d3GHR gene-specific primers, only 33% of 
OSCC cell lines tested expressed d3GHR mRNA (Fig.12), indicating that while the potential 
tumourigenic effects of autocrine GH signalling may be mediated by full-length GHR in a 
majority of cases, the d3GHR may play a role in a subset of patients. 
Immunoblotting for GHR proved challenging, most likely due to the insensitivity of the 
commercially-available GHR antibodies, lending credence to the use of antibodies produced 
in-house in other studies (Asa et al., 2007; Xu et al., 2011; Yang et al., 2007). Despite this, 
exogenous GHR induced by GHR overexpression by means of expression plasmid 
transfection indicated that exogenous GHR was detected at 110kDa (Fig.13A&B).A second 
band of 72kDa was also observed, which corresponds to the size of the intracellular domain 
following cleavage of the extracellular domain as observed by previous studies (Schantl et 
al., 2004) (Fig.13A).Expression plasmid PCR indicated that the insert was that of human GHR 
cDNA (Appendix A). Tunicamycin treatment indicated that the 110kDa band was most likely 
fully-mature, glycosylated, full-length GHR (Fig.17). Regardless of this, the 110kDa size was 
smaller than the 120-130kDa size corresponding to mature GHR seen in previous studies 
(Asa et al., 2007; Kerkhof et al., 2007; Ross et al., 1997; Stubbart et al., 1991; Wang et al., 
1992). Additionally, the overexpressed 110kDa GHR band was dysfunctional, as evidenced by 
the lack of phosphorylation in response to GH stimulation (Fig.21). This, coupled with the 
smaller than expected size of overexpressed GHR, may indicate that the expression plasmid 
was not cloned correctly. 
Endogenous GHR was detected at 120kDa (Fig.19, Fig.20, Fig.21), in agreement to the size of 
mature GHR detected in other studies (Asa et al., 2007; Kerkhof et al., 2007; Ross et al., 
1997; Stubbart et al., 1991; Wang et al., 1992). This band was only seen in one of the nine 
OSCC cell lines tested (Fig.15), further indicating the possible insensitivity of commercially-
available GHR antibodies. 
Interestingly, the 95kDa band deemed to be GHR by a previous study using the same 
antibody (Arturi et al., 2011), despite it being smaller than the reported 120-130kDa size 
seen in other studies, was detected in all OSCC cell lines tested. The same study, however, 
did not indicate whether the 95kDa band was mature GHR, and isoform, or a precursor form 
of GHR. Tunicamycin treatment indicates that this band is likely an unglycosylated, precursor 












means of siRNA did little to alter expression levels of the 95kDa band, however, inefficient 
knockdown may not be excluded. Also, the detection of a non-specific protein band of 95kDa 
may also explain the above knockdown results. Successful immunoprecipitations using the 
two GHR antibodies further confirm that the 95kDa band is that of GHR, albeit at much 
lower levels than prior to immunoprecipitation, further indicating the possible detection of 
an additional non-specific protein band at 95kDa. Taken together, this indicates while 
unglycosylated, precursor GHR is detected at 95kDa, the possible detection of a non-specific 
band also at 95kDa does not allow the conclusive detection of precursor GHR in OSCC. 
Additionally, only the Kyse 180 cell line exhibited detectable levels of mature GHR 
expression (Fig.15, Fig.21B). This could be due to the possible insensitivity of commercially-
available GHR antibodies, and/or the very short half-life of mature GHR (Baxter, 1985; 
Murphy and Lazarus, 1984). 
GHR knockdown by means of siRNA indicated that GHR plays a significant role in 
proliferation in Kyse 180 cells. A statistically significant decrease of 18% was seen compared 
to control knockdown (Fig.23B). Similar results were seen when antagonising GHR in GH-
expressing breast cancer cells, albeit to a greater extent (Kaulsay et al., 1999). IC50 values for 
both cisplatin and doxorubicin remain unchanged following GHR knockdown (Fig.24), in 
contradiction to previous studies showing that the anti-apoptotic effects of autocrine GH 
signalling are mediated by GHR (Minoia et al., 2012). These results suggest that while GHR 
plays a role in proliferation in Kyse 180 cells, the response of these cells to cisplatin and 
doxorubicin remain largely uninfluenced by the disruption of autocrine GH signalling by GHR, 
inferring that autocrine GH signalling mediated by GHR is not important for the 
chemosensitivity of these cells. Also, this could further infer that the potential tumourigenic 
effects of GH in these cells may be mediated by PRLR, a receptor that binds GH (Somers et 
al., 1994), and not by GHR. Additionally, since the above results were seen with only a 50% 
knockdown of total GHR mRNA levels (Fig.23C, Fig.24C), inefficient knockdown may not be 
excluded.  
Kyse 30 and Kyse 450 cells showed no changes in proliferation and IC50 following GHR 
knockdown (Fig.25-28), indicating that GH signalling via GHR, an in the case of Kyse 30 cells, 
via d3GHR is not important in these cells for proliferation and sensitivity to cisplatin and 
doxorubicin. Downstream ERK1/2 phosphorylation in response to GH stimulation revealed 












could be as a result of either the translation of dysfunctional GHR, or the lack of translation 
of GHR mRNA into protein. 
4.2 Conclusion 
RNA analysis indicates the ectopic expression of GH in a majority of OSCC cell lines. Several 
cell lines expressed mRNA for full-length GHR while few express mRNA for the d3GHR 
isoform, indicating a possible role of autocrine and/or paracrine GH signalling that may be 
mediated by full-length GHR in a majority of cell lines tested. While GHR knockdown did 
cause a decrease in proliferation in Kyse 180 cells, there was no change in IC50 values for 
cisplatin and doxorubicin, indicating that disruption of autocrine GH signalling through GHR 
only affects proliferation when investigating the effects of GH on only proliferation and 
chemoresistance. The failure of GH to elicit downstream signalling i  several cell lines 
indicates that while a majority of OSCC cell lines express GHR mRNA, this does not correlate 
to the expression of functional GHR protein. These results suggest that while the GH axis 
acting through GHR may play an important role in proliferation in a subset of patients, in a 
majority of cases GHR plays a very limited role, and may not be expressed as a functional 
protein. However, since only proliferation and chemoresistance were investigated, this 
cannot serve as an indication of the potential tumourigenic effects of GH in OSCC, and 
investigating additional tumourigenic markers are needed. Additionally, the inability to 
detect endogenous levels of mature and functional GHR is an indication of the insensitivity 




















4.3 Future Perspectives 
Given the ectopic expression of GH mRNA in OSCC, it would be interesting to investigate 
whether autocrine GH signalling plays a role in OSCC tumourigenesis, and whether it is 
mediated by PRLR. For this, the use of a PRLR-specific antagonist is needed (Xu et al., 
2011).Also, GHR and PRLR have shown to form functional heterodimers which are able to 
activate downstream signalling in response to GH (Xu et al., 2011). To test whether the 
potential tumourigenic effects of endogenous GH in OSCC is mediated by these 
heterodimers, antagonists will have to be used (Xu et al., 2011), given the inefficient 
knockdown achieved by siRNA transfection.  
As evidenced by this project, GHR did not play a role in chemoresistance in any of the three 
OSCC cell lines tested, and only contributed towards proliferation in one out of the three cell 
lines tested. This could be confirmed in a wider panel of cell lines using a GHR antagonist. 
Additionally, knockdown of GHR did not significantly reduce activation of downstream 
signalling in response to GH, possibly indicating that effects of GH are not mediated 
exclusively by GHR. This could also be better explored by using antagonists specific to GHR. 
Additionally, since only proliferation and chemoresistance were investigated in this project 
and therefore cannot be a true reflection of the potential tumourigenic effects of GH in 
OSCC, it would be interesting to investigate whether GH/GHR signalling may play a role in 
other tumourigenic markers such as metastasis, invasion, angiogenesis, epithelial-to-
mesenchymal transition, and anchorage-independent growth. 
Given the possible identity of the 120kDa band detected in Kyse 180 as that of mature GHR, 
tunicamycin treatment within this cell line would be needed to investigate its glycosylation 
status and thus further confirm its identity as mature, glycosylated GHR. The band’s 
response to serum starvation in Kyse 180 cells would further confirm this. Additionally, given 
the possible identity of the 95kDa band as unglycosylated, precursor GHR, a time and dose-
dependent knockdown of GHR in differing cell lines would serve to confirm this. To minimise 
the effects of inefficient knockdown in such experiments, a suitable cell line shown to 
respond to GHR knockdown by greatly decreasing GHR mRNA levels would be needed. 
Evidence in this project suggests that the 75kDa band detected by Mab 263 is likely a non-
specific protein band. However, there is also evidence suggesting its identity as a previously 












downstream signalling when stimulated with GH (Fig.29), while expressing relative low levels 
of full-length and/or d3GHR mRNA (Fig.12, panel flGHR/d3GHR) and relatively high levels of 
the 75kDa band (Fig.14A) when compared to Kyse 180, a cell line shown to respond to GH 
stimulation. Additionally, this dominant negative isoform of GHR would function in a similar 
manner to that of the 1-279GHR isoform, since it lacks the necessary intracellular domain for 
downstream signal transduction, as evidenced by the lack of detection by the B12 antibody. 
To further investigate the possible identity of the 75kDa band as a dominant negative 
isoform of GHR, knockdown of GHR mRNA and immunoblotting with the Mab 263 antibody 
will be needed. Additionally, it would be interesting to investigate its dominant negative role 
in OSCC by selecting two cell lines, one expressing low levels of the 75kDa band, and one 
expressing high levels, and investigating the difference in ERK1/2 phosphorylation in 
response to GH between the two. 
As final confirmation of the potential tumourigenic role of endogenously-produced GH in 
OSCC, it would be interesting to investigate patient material for GH mRNA expression by 
qRT-PCR, and, if possible, GH protein expression. Additionally, it would be interesting to 
investigate GHR mRNA expression by qRT-PCR and localisation by either 
immunohistochemistry and/or immunoblotting of nuclear-fractionalised protein lysates 
obtained from patient material. This would be done for both normal, and tumour biopsies 


























MATERIALS AND METHODS 
 
5.1 Transformation and Plasmid Isolation 
5.1.1 Transformation 
Competent JM109 E.coli cells (Promega, USA) were transformed with the GHR expression 
vector (kindly supplied by Andrew Brooks). The JM109 strain of E.coli cells allows for better 
transformation efficiency and improved plasmid yield since endonuclease A activity is 
abolished within this strain(Taylor et al., 1993).  
Plasmids arrived by mail blotted on filter paper. The filter paper was then immersed in TE 
buffer (pH 8) (Appendix B) allowing the resuspension of the expression plasmids. The 
plasmid concentration within the suspensions was then quantified using the NanoDrop™ 
2000c spectrophotometer (Thermo Scientific, USA). 50ng of each plasmid was then used to 
transform 20µl of JM109 E.coli cells. Upon the addition of the plasmid suspension to the 
cells, the mixture was allowed to chill on ice for 10min. Cells were then transformed at 42oC 
for 2min before chilling on ice for 2min. 900µl of Luria broth (LB) (no ampicillin) (Appendix B) 
was then added prior to incubation at 37oC in a shaker set at 275rpm for 1hr. 20µl, 100µl, 
and 500µl of cells were then plated on ampicillin-containing agar plates (100μg/ml) 
(Appendix B) which were incubated overnight at 37oC. Colonies were then selected and 
inoculated in 5ml ampicillin-containing (100μg/ml) LB. Plasmid from these colonies were 
then isolated using the PureYield™ Plasmid Miniprep System kit (Promega, USA) following 
overnight incubation at 37oC shaking at 200rpm. Following confirmation of desired 
transformation, 1ml aliquots of 15% glycerol transformed E.coli cells were made and stored 
















5.1.2 Plasmid Isolation, Restriction Enzyme Digest, and Agarose Gel Electrophoresis 
The plasmid isolation was performed as manufacturer’s instructions and is based on alkaline 
lysis of bacterial cells followed by the adsorption of DNA onto silica in the presence of high 
salt.  Successful colonies containing desired GHR plasmid were initially confirmed using 
restriction enzyme digest on the plasmids isolated from the colonies (SspI). Additionally, 100 
copies of each GHR, d3GHr, and GH expression plasmid underwent PCR using gene-specific 
primers for GHR, d3GHR, and GH respectively, to further confirm desired colonies. Digested 
and PCR products from each expression vector underwent agarose gel electrophoresis as 
described below.  
For transfections in mammalian cells, plasmid stocks of GHR expression plasmid was made 
using the PureYield™ Plasmid Midiprep System kit (Promega, USA), as per manufacturer’s 
instructions. This kit allowed for more plasmid to be isolated from more transformed E.coli 
cells than would have been possible with the PureYield™ Plasmid Miniprep System kit. Final 
plasmid stocks of all 3 expression vectors were finally quantified using the NanoDrop™ 
2000c spectrophotometer and stored at -20oC for long term-storage. 
5.2 RNA Isolation and Quantification 
5.2.1 RNA Isolation 
Ribonucleic acid (RNA) was isolated from cells using the QAIzol™Lysis Reagent (QAIGEN, 
GER) as per manufacturer’s instructions. The lysis reagent, consisting of phenol and 
guanidine thiocyanate, is designed to optimally extract RNA from cells and tissue by 
facilitating lysis of fatty tissues and cell membranes, and inhibiting RNases.  
 
Briefly, the protocol entailed washing the cells with 4oC 1x phosphate buffered saline (PBS) 
(Appendix B) before adding QAIzol (volumes of QAIzol added to size of culture dishes 
bellow), transferring the lysate to a Diethylpyrocarbonate (DEPC)-treated Eppendorf tube, 
and allowing 5min incubation at RT. This was then stored at -80oC prior to RNA isolation. 
RNA was then isolated by means of a chloroform separation and isopropanol precipitation. 
The addition of chloroform (one-fifth the volume of QAIzol used) allowed the dissociation of 
two phases, the upper aqueous phase and the lower organic phase following centrifugation 












transfer of the aqueous phase to a new DEPC-treated Eppendorf tube, isopropanol was 
added (half the volume of QAIzol used) to allow precipitation of the RNA. The RNA was then 
centrifuged out of solution at 12000g for 15min at 4oC and washed with 75% ethanol made 
up in DEPC-treated H2O (Appendix B). The RNA pellet was then allowed to air-dry before 
being resuspended in 20µl DEPC-treated water and stored at -80oC. 
 












5.2.2 RNA Quantification 
 
The RNA was quantified using the NanoDrop™ 2000c spectrophotometer (Thermo Scientific, 
USA). Absorbance readings at 280nm, 260nm, and 230nm were used to determine protein 
contamination and organic solvent contamination. Protein contamination was investigated 
using the 260/280 ratio. Pure RNA achieves a value of 2, and lower values are an indication 
of protein contamination within the sample. Contamination by organic solvents used in RNA 
extraction could also be investigated by means of the 260/230 ratio. A pure sample of RNA 
would achieve a value of 1.8, with lower values indicating possible organic sample 
contamination which could interfere with downstream processes such as cDNA conversion. 





















5.2.3 RNA Agarose Gel Electrophoresis 
 
To assess the integrity of the isolated RNA, 1µg was analysed by RNA gel (Appendix B) 
electrophoresis. RNA was suspended in RNA loading buffer (Appendix B) and heated at 55oC 
for 5min. The heated sample then underwent electrophoresis at 70V for 1hr and was 
visualised by means of ultraviolet light (UV) transilluminator. The absence of smearing and a 
clear ratio of 2:1 for the 28S:18S ribosomal RNA subunits indicated that the RNA was of good 
quality and did not harbour significant degradation. 
 
5.3 DNase Treatment 
 
Since genomic DNA (gDNA) contamination is common to QAIzol-isolated RNA, isolated RNA 
underwent DNase treatment using the TURBO™ DNA-free DNase Treatment Kit (Applied 
Biosystems, USA) as per manufacturer’s instructions. The kit allows for degradation of DNA 
by an engineered version of the wild type DNase I enzyme which has a greater catalytic 
efficiency, followed by the removal of the enzyme and divalent cations that may catalyse 
RNA degradation by means of the DNase Inactivation Reagent, without heating of the 
sample.  
 
5µg of RNA was diluted to a concentration of 200ng/µl and subjected to DNase digest by 1u 
of the TURBO™DNase I enzyme. The catalytic reaction occurred at 37oC for 30min followed 
by the addition of 2.5µl of the DNase Inactivation Reagent. The sample was then centrifuged 
at 10000g at RT for 1.5min, and the supernatant containing the DNase-treated RNA was 





















5.4 First-strand cDNA Synthesis 
 
DNase-treated RNA was subjected first-strand complementary DNA (cDNA) synthesis using 
the ImProm-II™ Reverse Transcription System kit (Promega, USA) as per manufacturer’s 
instructions. The kit allows for efficient synthesis of cDNA using an optimised set of reagents 
and entails the annealing of either random hexomer primers (RHP) or Oligo(dT) subsequent 
to cDNA synthesis by the ImProm-II™ Reverse Transcriptase enzyme, followed by  heat-
inactivation of the enzyme. 
 
Briefly, 1µg of DNase-treated RNA was added to 0.5µg RHP and allowed to denature at 70oC 
for 5min. The reaction was then chilled on ice for 5min. A mastermix of MgCl2 and the 4 
deoxyribonucleotides to a final concentration of 2mM and 0.5mM respectively, was made 
along with 1l ImProm-II™ Reverse Transcriptase enzyme and 20U Recombinant RNasin® 
Ribonuclease Inhibitor and added to the primer-RNA reaction. he sample was then allowed 
to incubate at 25oC for 5min to allow primer annealing. cDNA synthesis was then achieved 
by subjecting the reaction to 42oC incubation for 1hr. Following reverse transcription, the 




























5.5 Quantitative Real-time Polymerase Chain Reaction 
 
mRNA expression was investigated and quantified by means of quantitative real-time 
polymerase chain reaction (qRT-PCR), following reverse transcription. This procedure 
involved the use of primers that anneal specifically to sequences within a template to 
amplify the desired product. This is achieved by exposing the reaction to several cycles of 
temperatures to allow primer annealing, product extension, and denaturation.The 
comparative threshold cycle (CT) method was used for the calculation of expression fold 
changes between samples. 
 
Gene-specific primers were used and were synthesized by the Oligonucleotide Synthesis 
Facility, University of Cape Town, and 20µM stocks for each primer were prepared. GHR, 
d3GHR, GH, and GAPDH gene-specific primer sequences, final concentration used, annealing 
temperatures, PCR cycles, and PCR product sizes are indicated below. 2µl of converted cDNA 
was added to a reaction already containing gene-specific primers, 9.5µl Fast SYBR® Green 
Master Mix (Invitrogen, USA) and made up to a total volume of 20µl with SABAX® water 
(Adcock Ingram, USA) per sample. qRT-PCR was performed on the StepOne™ Real-Time PCR 
System (Applied Biosystems, USA). For all PCRs, initial denaturation occurred at 95oC for 
3min, primer annealing occurred at the indicated temperatures for 20sec, and denaturing 
after each cycle occurred at 95oC for 1sec. Extension occurred during the temperature 
increase from primer annealing to denaturation. mRNA was then quantified after 
standardising to the housekeeping gene, GAPDH. Relative CT values were then analysed 























Table 2: Gene-Specific Primer sequences and PCR conditions 











flGHR Forward CTC AAC TGG ACT TTA CTG AAC G 1 62 30 454 
(Kaulsay et 
al., 1999) 
  Reverse AAT CTT TGG AAC TGG AAC TGG G           
d3GHR Forward CCT ACA GGT ATG GAT CTC TGG 1 60 40 flGHR:       420 
(Sobrier et 
al., 1993) 
  Reverse CCA CCA TTG CTA GTT AGC TT       d3GHR:    354   
GH Forward CCG ACA CCC TCC AAC AGG GA 0.2 62 40 343 
(Kaulsay et 
al., 1999) 
  Reverse CCT TGT CCA TGT CCT TCC TG           
GAPDH Forward GCC TGC TTC ACC ACC TTC  1  55  40  201  Unpublished 
  Reverse GGC TCT CCA GAA CAT CAT CC           
 
5.6 Agarose Gel Electrophoresis 
PCR products generated from cDNA samples and expression plasmids were visualised by 
means of ethidium bromide staining and observation by means of a UV transilluminator, 
since ethidium bromide intercalates within DNA and is fluorescent under UV. PCR products 
were separated by electrophoresis in either a 2% or 3% agarose gel containing 10mg/ml 
ethidium bromide for 1hr at 100V following the addition of 6X DNA loading dye (Appendix B) 
to the PCR reaction. Additionally, digested GHR expression plasmidwas subjected to 
electrophoresis in a 0.8% agarose gel containing 10mg/ml ethidium bromide following 
digestion by their respective restriction enzymes. 
5.7 Sequencing 
Appropriate amounts of PCR products were used as templates for labelling and sequencing 
using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, USA) and ABI 
PRISM® 3100 Genetic Analyzer (Applied Biosystems, USA). Provided protocols were followed 
accordingly. 
The sequencing reaction works on the principle of cycle sequencing. This involves the 
denaturation of double-stranded DNA at 96oC for one minute, annealing of the primers, and 
extension by incorporation of either deoxynucleotides or fluorescent dideoxynucleotides to 
form a fluorescent dye-labelled product. Once a dideoxynucleotide is randomly 
incorporated, elongation of that particular strand is terminated. Therefore, after the PCR of 
25 cycles is complete, one is left with PCR fragments all of different sizes depending on when 












Before the sequencing reaction could take place, the PCR product band was cut out of the 
agarose gel and purified using the Wizard® SV Gel and PCR Clean-Up System (Promega, USA) 
as per manufacturer’s instructions. The kit allowed for the removal of free deoxynucleotides 
and primers that could interfere with the sequencing. Briefly, the protocol entailed melting 
the agarose gel slice in the Membrane Binding Solution supplied with the kit, followed by 
passing the DNA-solution mix through a DNA-binding silica membrane, washing the 
membrane with the provided Membrane Wash Solution, and eluting the bound DNA with 
DNase-free water. The eluted DNA was then quantified using theNanoDrop™ 2000c 
spectrophotometer and stored at -20oC. 
 
An appropriate amount of purified PCR product was then added to 2µl of BigDye® 
Terminator Mix, 4µl BigDye® Buffer, and 4µM of either the forward or the reverse primer 
used to generate that PCR product. The BigDye® Terminator Mix contained the necessary 
deoxynucleotides and dideoxynucleotides. The sequencing reaction then underwent PCR 
with an initial denaturing step at 96oC for 3min, followed by 25 cycles of 96oC for 30sec, 
primer annealing at 50oC for 15sec, finally followed by extension at60oC for 4min. 
 
The sequencing reaction was then analysed using ABI PRISM® 3100 Genetic Analyzer 
(Department of Human Genetics, University of Cape Town) which works on the principle of 
capillary electrophoresis. Briefly, this involves the separation of differently-sized 
fluorescently-labelled sequences. The shorter fragments are the first to be detected by the 
laser followed by larger fragments. This results in the fragment being sequenced in the 5' to 
3' direction. Since each of the four possible dideoxynucleotidesare independently labelled, a 
computer is then able to assemble a chromatogram, from which the sequence of the PCR 
fragments can be read. The generated sequence was then compared to the expected PCR 



















5.8 Cell Culture 
 
5.8.1 Cell Lines 
 
The human oesophageal squamous-cell carcinoma cell lines WHCO1, WHCO5 andWHCO6, 
derived from South African patients, were a gift from Prof. R. Veale(University of 
Witwatersrand). All Kyse cell lines used were previously established(Shimada et al., 
1992),and purchased from German ResourceCentre for Biological Material, DSMZ GmbH 
(Braunschweig, GER). 
 
5.8.2 Cell Culture 
 
All cell lines used were cultured at 37oC in a humidified incubator which was also supplied 
with a 5% carbon dioxide and 95% air gas mixture. Cells were cultured Gibco® Dulbecco’s 
Modified Eagle Medium (DMEM) (Invitrogen, USA) containing 10% heat-inactivated foetal 
bovine serum (FBS), penicillin (100U/ml), and streptomycin (100µg/ml) (Appendix B). Media 
with these additives will be called complete media from here on. 
 
Frozen stocks of cells were prepared by allowing cells to reach 80% confluency, before media 
was removed and washed with trypsin/EDTA (Difco, USA) heated up to 37oC. After washing, 
cells were then trypsinised with 5ml trypsin/EDTA at 37oC for 2min. Trypsin/EDTA was then 
inactivated by adding an equal amount of complete media, followed by transfer of the cells 
into a sterile 12 ml tube. Cells were then centrifuged at 1000rpm for 5min. The supernatant 
was then removed from the cell pellet and resuspended in 2.7ml complete media. 0.3ml of 
DMSO was then added to achieve a final concentration of DMSO of 10% (v/v). 1ml of the 
cell/DMSO mixture was then aliquoted per cryotube and stored at -80oC for 24hrs. Frozen 


















5.8.3 Cell Culture Passaging 
 
Frozen cell stocks were thawed by incubation in a water bath set at 37oC. Once completely 
thawed, cells were added to a 10cm cell culture dish containing 10ml of complete media 
already pre-warmed to 37oC. Cells were then incubated overnight at 37oC, followed by a 
change of complete media. Cells were then cultured in this state with regular changing of 
media for future experiments, or trypsinised and split into new cell culture dishes as needed. 
 
5.8.3 Mycoplasma Testing 
 
Cells were tested for Mycoplasma contamination twice a year. The test briefly involved 
culturing cells in penicillin and streptomycin-free DMEM for 3 days, before being plated on 
flamed coverslips. Cells were then allowed to settle and culture for 2 days. Cells were then 
fixed with fixing solution (Appendix B) and stained with Hoechst fluorescent DNA-binding 
stain (Appendix B) for 30sec. Coverslips were then wash d with water and mounted on 
slides. Stained cells were visualised on the Zeiss Axiovert 200 Fluorescent microscope (Carl 
Zeiss, Germany). The absence of small fluorescent spots between stained nuclei indicated 



























5.9 Expression Plasmid and siRNA Transfections 
 
The Kyse 150 cell line was transfected with the GHR expression plasmid using GeneCellin™ 
Transfection Reagent (BioCellChallenge, USA). The reagent allows for higher delivery 
efficiencies of plasmid DNA into cell lines and primary cells compared to other lipid and 
polymer based transfection reagents, with reduced cytotoxicity. 
 
100000 cells were plated per 35mm cell culture dish and incubated at 37oC overnight. The 
next day, cells were transfected overnight using 0.5µg of plasmid as follows; 0.5µg of 
plasmid was diluted in 50µl of serum-free DMEM media in a 1.5ml Eppendorf tube. 2µl of 
GeneCellin™ Transfection Reagent was then immediately added and allowed to incubate at 
RT for 15min. The mixture was then added to the cells in 2ml of complete media drop-wise 
and incubated overnight at 37oC. The next day, protein and/or RNA was either isolated or 
the media changed to 2ml complete media for future use. 
 
GHR siRNA (Sigma, USA) was transfected using the Transfectin™ Lipid Reagent (BIO RAD, 
USA). The lipid-based transfection reagent, which is a mixture of a proprietary cationic 
compound and a co-lipid, allows for optimised intracellular delivery of nucleic acids into 
cultured mammalian cells. 
 
150000 cells were plated per 35mm cell culture dish and incubated at 37oC overnight. The 
next day, cells were transfected for 6hrs using 20nM amounts of siRNA as follows; 0.625µl of 
the Transfectin™ Lipid Reagent was added to 50µl of serum and penicillin and streptomycin-
free media in a 1.5ml Eppendorf tube and allowed to incubate at RT for 5min. siRNA was 
added to the mixture to a final concentration of 20nM and incubated at RT for 20min. The 
mixture was then added drop-wise to cells in 1ml complete media and allowed to transfect 
for 6hrs, followed by the removal of the media and the replacement with 2ml complete 
media. 
 
If different sized culture dishes were used for transfection other than the 35mm dishes, the 
protocols above were scaled down/up according to area of the dish used compared to the 













5.10 Protein Isolation 
 
Protein was isolated from plated cells (with varying densities according to the experiments 
needed) by firstly removing existing media and washing cells twice with 1xPBS cooled at 4oC 
(volumes of 1xPBS used per wash was exactly half of the volume of complete media used to 
culture the cells in that specific dish). Radioimmnoprecipitation assay buffer (RIPA) with the 
indicated additives (Appendix B) (volume of RIPA buffer used to culture dish size table 
below) was added to the cells. Cells were then scraped using a cell scraper and transferred 
to a 1.5ml Eppendorf tube. Cells were then subjected to sonication for 15sec on ice, followed 
by centrifugation at 10000g at 4oC for 10min. The supernatant was then transferred to a 
clean Eppendorf tube, and protein concentration was quantified using the Bichinchoninic 
acid (BCA) Protein Assay Kit (Thermo Scientific, USA) as per manufacturer’s instructions. 
Absorbance at 595nm was then measured, and protein concentration was calculated using a 
set of standard bovine serum albumin (BSA) concentrations. Isolated protein was stored at -
80oC for long-term storage. 
 
Table 3: Volume of RIPA used to size of dish 
Dish Diameter 
(mm) 































5.11.1 Sodium dodecyl-sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Protein samples were prepared by adding a specific amount of protein to 5X loading dye 
(Appendix B) and made up to a specific volume with RIPA buffer. The prepared samples were 
then heated at 850C for 5min before loading onto a 7.5% polyacrylamide gel (Appendix B). 
Heating of the sample in the presence of β-mercaptoethanol and SDS ensured that the 
proteins were in their denatured, reduced state allowing for the separation of the proteins 
present in the sample based only on their respective sizes. Proteins were then 
electrophoresed at 150V for 2hrs in 1X Running Buffer (Appendix B). Following this, 
separated proteins within the gel were then transferred onto a Hybond™-ECL™ 
nitrocellulose membrane (Amersham Life Sciences, UK) at 100V for 1.5hrs in 1X Transfer 




Following protein transfer onto the nitrocellulose membrane, the membrane was then 
blocked for 1hr at RT in blocking solutions described below. All blocking solutions were 
diluted in 0.1% Tween TBS (TBST). Membranes were then probed with the desired primary 
antibody at 4oC O/N with agitation. Membranes were then washed 3 times with TBST 
(Appendix B) for 5min each, before the addition and incubation with HRP-conjugated 
secondary antibody. Incubations with secondary antibody occurred at RT for 1hr with 
agitation. Following incubation with the secondary antibody, the membrane was once again 
washed 3 times with TBST for 5min each with agitation. Below is a table summarising the 



















Table 4: Blocking and Immunoblotting Conditions for Antibodies  
Primary 
Antibody 





monoclonal Mouse 5%Milk+2.5%BSA 1:250 5%Milk/TBST Santa Cruz  sc-137184 
GHR 
(Mab263) 
monoclonal Mouse 5%Milk 1:1000 TBST Abcam  Ab11380 
β-Tubulin polyclonal Rabbit 5%Milk 1:1000 TBST Santa Cruz sc-9104 
HA polyclonal Mouse 5%Milk 1:5000 5%Milk/TBST Santa Cruz sc-805 








EGFR polyclonal Rabbit 5%Milk 1:1000 2.5%Milk/TBST Santa Cruz sc-03 
 
Table 5: Immunoblotting Conditions for Secondary Antibodies 
Secondary 
Antibody 
Dilution Diluent Company 
Catalogue 
Number 
Goat α-Mouse 1:1000 5%Milk/TBST Abcam  170-6516 




Protein bands of interest were detected using SuperSignal® West Pico Chemoluminescent 
Substrate (Thermo Scientific, USA) as per manufacturer’s instructions. This involved 
incubating the membrane for 5min at RT before detection. For detection, AGFA CU-BR 
Medical X-ray film (AGFA, Belgium) were exposed to the membrane. The X-ray films were 
then developed until bands of interest were seen, before being fixed using a fixative agent. 
 
5.11.4 Membrane Stripping 
 
Membranes could be reprobed for different proteins following stripping. Membranes were 
stripped in β-mercaptoethanol stripping buffer (Appendix B) for 30min at RT with agitation, 
after prior heating of the stripping buffer at 50oC for 30min. Following stripping, membranes 
were washed 3 times with TBST for 5min at RT each time with agitation. Membranes were 
then processed as above starting with blocking according to the conditions stipulated above 















5.11.5 Densitometry Analysis 
 
Following autoradiographic detection of the membranes, the band intensities of bands of 
interest were quantified by densitometry using the software ImageJ. Protein expression was 




GHR was immunoprecipitated from 1000µg of protein using the 10µg of the Mab 263 
antibody in a total volume of 500µl made up with RIPA buffer containing the phosphatase 
and protease inhibitors. The protein-antibody mix was incubated at 4oC O/N with continuous 
rotation. 100µl of Protein G-Sepharose beads (Calbiochem, USA) was then added to allow 
binding of the protein-antibody complex to the beads, and allowed to incubate at 4oC O/N 
also with continuous rotation. The protein-antibody-bead solution was then centrifuged at 
3000rpm at 4oC for 2min. The supernatant was then removed leaving only the protein-
antibody-bead complex. The complex was then washed 3 times with 1XPBS chilled at 4oC at 
3000rpm at 4oC for 2min. 35µl of 2X loading dye (Appendix B) was added, followed by 
heating at 95oC to allow dissociation of the protein-antibody-bead complex. Following 
centrifugation at RT at 3000rpm for 2min, 30µl of supernatant was electrophoresed and 
immunoblotted using the GHR B12 antibody as described above. The protocol was scaled 


























GHR expression and localisation was determined by means of immunocytochemistry. The 
method allows for detection and localisation of native proteins within fixed cells by means of 
antigen detection by specific antibodies. 
 
100000 cells were plated per 35mm cell culture dish the day before on coverslips sterilised 
by means of flaming. Cells were then fixed with either 4% paraformaldehyde (PFA) 
(Appendix B) or absolute methanol. In the case of PFA fixation, cells were washed with 
1xPBS, and coverslips were immersed in 4% PFA and incubated at RT for 20min. In the case 
of methanol fixation, cells were washed with 1xPBS, and coverslips were immersed in 
absolute methanol chilled at -20oC, and allowed to incubate at -20oC for 5min. Cells were 
then washed 3 times with 1xPBS for 10min per wash on shaker at RT. When cells were fixed 
with PFA, they underwent permeablisation by means of incubating cells at RT for 5min in 
0.5% Triton-X 100 made up in 1xPBS. Permeabilised cells were then quenched with 50mM 
NH4Cl made up in 1xPBS for 5min at RT.  
 
Cells were then blocked in either 0.2% gelatin or 1%BSA, both made up in 1xPBS. Two 
different blocking conditions were used, either 1hr or O/N. In the case of 1hr blocking, cells 
were immersed in either blocking solution and allowed to incubate for 1hr at RT on a shaker. 
When cells were blocked O/N, cells were immersed in either blocking solution and allowed 
to incubate O/N at 4oC on a shaker. 
 
Following blocking, cells were then incubated with a range of primary antibody 
concentrations (1:50 to 1:500, made up in blocking solution) for either 1hr at RT or O/N at 
4oC, by means of inverting the coverslips on 100l drops of antibody dilutions. The primary 
antibody used for GHR localisation was Mab 263 (Abcam, USA). All antibody incubations 
were done in a humidifying chamber in the dark. Following incubation with primary 
antibody, cells were washed 3 times for 10min each wash in 1xPBS. Coverslips were then 
incubated in 1:500 dilution of Alex Fluor® 488 goat anti-mouse secondary antibody 
(Invitrogen, USA) at RT for 90min in a humidifying chamber. Nuclei were counterstained with 
100ng/ml4',6-diamidino-2-phenylindole (DAPI) (Sigma Aldrich, USA) diluted in 1xPBS, at RT 












with Mowiol®4-88 (Polysciences Inc., USA) (Appendix B). Slides were kept at 4oC in a dark 
chamber for long-term storage. 
 
5.14 Proliferation Assay 
 
The 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Sigma Aldridge, 
USA) colourimetric assay was used as a measure for cellular proliferation. Upon incubation 
of live cells with the MTT reagent, the yellow tetrazolium salt within the reagent is converted 
into purple formazan crystals in the mitochondria of living cells. The use of MTT is therefore 
strictly an indication of mitochondrial activity within living cells only at a specific time point, 
however, when the assay is conducted over a number of time points, the increase/decrease 
in mitochondrial activity is directly proportional to the cellular proliferation/death 
experienced by those cells within that range of time points. 
 
1500 cells were plated in complete media per well in a 96-well plate. Cells were plated in 
triplicate for each condition tested, and 10µl MTT (5μg/ml) (Appendix B) was added per well 
at the predetermined time points. The cells were then allowed to incubate for 4hrs at 37oC 
in a humidified incubator before the addition of 100µl solubilising solution (Appendix B). The 
solubilising solution allowed for the lysing of the cells and the solubilisation of the formazan 
crystals. Once the solubilising solution was added, cells were allowed to incubate O/N at 
37oC in a humidified incubator. Absorbance at 595nm was then read using the Bio-Tek EL800 
Microplate reader (Labtech, UK) in conjunction with the Gen5 Data Analysis software. The 
absorbance value measured was a quantification of mitochondrial activity at that time point. 
This was then done at several predetermined time points, and the increase/decrease in 
absorbance was a representation of the proliferation/death experienced by those cells 
within that range of time points. Proliferation/death curves were then plotted and analysed 


















5.15 Growth Hormone Stimulation 
 
Cells were plated and allowed to culture O/N in complete media. Cells were then serum 
starved with DMEM media supplemented with 0.1% FBS, penicillin (100U/ml), and 
streptomycin (100μg/ml) for 24hrs. Recombinant human GH (500ng/ml) (Sigma Aldrich, 
USA) was then added and allowed to incubate at 37oC for 5min before extracting 
RNA/protein as described above. 
 
5.16 Chemotherapeutic Drug Treatments 
 
Cisplatin was prepared to a final concentration of 1.6mM in 1xPBS and stored at -80oC. 
Doxorubicin was prepared to a final concentration of 50mM in sterile dH2O and stored at -
80oC. Cells used in drug treatment assays were plated at 3000 cells in complete media per 
well in a 96-well plate, and allowed to incubate O/N at 37oC in a humidified incubator.  A 
range of drug concentrations was then added and allowed to incubate at 37oC for 48hrs in a 
humidified incubator before the addition of MTT and the analysis of absorbance at 595nm as 
described above. Concentrations used for cisplatin treatments ranged from untreated to 
150μM while concentrations used for doxorubicin treatments ranged from untreated to 
10μM . Cells were plated in triplicate per concentration of drug used. Absorbance readings 
were then used for analysis using the GraphPad Prism® software, to generated dose 
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Appendix A- PCR Product Sequences and Additional Immunoblots 
 
Figure 29: Sequencing and alignment of the GH PCR product to human GH cDNA. The PCR product generated using T47D cDNA as 

























Figure 30: Sequencing and alignment of the flGHR PCR product to human GHR cDNA. The PCR product generated using T47D cDNA as 
























Figure 31: Sequencing and alignment of the GHR PCR product using the d3GHR-specific primers to human GHR cDNA. The PCR product 
generated using T47D cDNA as template and d3GHR-specific primers, and its alignment to human GHR cDNA, indicates that the 410bp 


























Figure 32: Sequencing and alignment of the d3GHR PCR product using the d3GHR-specific primers to human GHR cDNA. The PCR product 
generated using T47D cDNA as template and d3GHR-specific primers, and its alignment to human GHR cDNA, indicates that the 354bp 
product corresponds to human d3GHR. The missing 66bp in the PCR product sequence compared to the GHR cDNA sequence correlates to 

























Figure 30: Sequencing and alignment of the GHR-pcDNA3.1 expression plasmid and human GHR cDNA. 100 copies of the GHR expression 
plasmid underwent PCR using the flGHR-specific primers. The PCR product was sequenced and aligned to the human GHR cDNA sequence. 






















Figure 31: Immunoblotting Kyse 150 cells transfected with GHR and empty expression vector. Kyse 150 cells were either transfected with 
the GHR-pcDNA3.1 (Kyse 150+GHR) or empty pcDNA3.1 (Kyse 150+Empty) expression vector and protein lysates were immunoblotted as 


























Appendix B- Solutions 
 
1. Transformation and Plasmid Isolation 
 
TE Buffer (pH8.0) 500ml 
5ml 1M Tris-HCl (pH8.0) 
1ml 0.5M EDTA (pH 8.0) 
 





Sterilize by autoclaving 
Store at room temperature 
 
Ampicillin-containing LB 
1:1000 dilution of filter-sterilized ampicillin (100mg/ml) into LB 
Store at room temperature 
 
Ampicillin-containing Agar (200ml) 
3g Agar 
200ml LB 
Sterilize by autoclaving 
Add 200µl ampicillin (100mg/ml) once cool 
















2. RNA Isolation and Electrophoresis 
 
DEPC-Treatment 
0.1% DEPC in distilled H2O 
Stir for one hour 
Soak pipette tips and microfuge tubes in DEPC-treated H2O overnight 
Remove as much water as possible and autoclave 
 
DEPC-Treaded H2O 
0.1% DEPC in distilled H2O 
Stir for one hour 
Autoclave 
 
RNA Gel (50ml) 
0.75g Agarose 
42ml dH2O 
Heat and allow to cool 
5ml 10X MOPS 
2.7ml Formaldehyde 
 
10X MOPS (1000ml) 
41.86g MOPS  
16.6ml 3M NaAcetate 
20ml 0.5M EDTA (pH8.0) 


















2x RNA Loading Dye 
0.72ml Formamide 
0.16ml 10X MOPS 
0.26ml Formaldehyde 
0.18ml dH2O 
0.1ml 80% Glyerol 
0.08ml Bromophenol Blue 
Store at -80oC 
 
3. DNA Electrophoresis 
 
2% Agarose Gel (50ml) 
1g Agarose 
50ml 1X TAE 
3μl Ethiduim Bromide (10mg/ml) 
 
0.8% Agarose Gel (50ml) 
0.4g Agarose 
50ml 1X TAE 




28.5ml Glacial Acetic acid 
50ml 0.5M EDTA (pH8.0) 

















6X DNA Loading Dye 
25mg Bromophenol Blue 
25mg Xylene Cyanol 
3.3ml Glycerol 
6.7ml dH2O 
Add Tris until blue 
 
4. Cell Culture 
 





Make up to 500ml with dH2O 
Dilute to 1x PBS when needed 
 

























Freezing Media (10ml) 
9ml Complete DMEM Media 








2ml 1M Tris (pH 7.5) 
2g Na deoxycholate 
 
Complete RIPA (1ml) 
825μl RIPA 
100μl 10X Protease Inhibitor (Sigma, USA) (104mM AEBSF. 80μM Aprotinin, 4mM Bestatin, 1.4mM E-
46, 2mM Leupeptin, 1.5mM Pepstatin) 
50μl  1MNaF 
20μl 0.1M Na3VO4 
5μl 100mM PMSF 
 
Resolving Gel Buffer (200ml) 
36.2g Tris 
0.8g SDS 
pH 8.9 and make upto 200ml with dH2O 

















Stacking Gel Buffer (100ml) 
5.9g Tris 
0.4g SDS 
pH 8.0 and make up to 100ml with dH2O 
Store at 4oC 
 
7.5% Denaturing Polyacrylamide Separating Gel 
3ml Resolving Gel Buffer 
2.25ml 30% Acrylamide 
3.75ml dH2O 
180μl 0.1% APS 
18μl TEMED 
 
5% Denaturing Polyacrylamide Stacking Gel 
1.5ml Stacking Gel Buffer 
1ml 30% Acrylamide 
3.5ml dH2O 
60μl 0.1% APS 
6μl TEMED 
 
5X Protein Loading Dye (50ml) 
1.75g Tris 
30ml Glycerine 
pH 6.8 and make up to 40ml with dH2O 
5g SDS 

















2X Protein Loading Dye (10ml) 
4ml 5x Protein Loading Dye 
6ml 1X PBS 
 




Make up to 1000ml with dH2O 
Dilute to 1X Running Buffer when needed 
 
10X Transfer Buffer 
144g Glycine 
38g Tris 
Make up to 1000ml with dH2O 
 
1X Transfer Buffer (1000ml) 




10X TBS (1000ml) 
60.5g Tris 
87.6g NaCl 
pH7.5 and make up to 1000ml with dH2) 
 
TBST (1000ml) 
100ml 10X TBS 
900ml dH2O 













Β-Mercaptoethanol Stripping Buffer (200ml) 
1.4ml β-Mercaptoethanol 
4g SDS 
12.5ml 1M Tris (pH6.7) 




4% Paraformaldehyde (PFA) 
16g PFA 
80ml dH2O 
Cover with foil and stir for 1hr not letting temperature exceed 60oC 
Add 10M NaOH until clear 
Filter-sterilise 
Adjust to pH 7.0 
Store in 2.5ml aliquots at -20oC 




100ml 1X PBS 
 
Mowiol 4-88 
2g Mowiol 4-88 
2ml Glycerol 
4ml dH2O 
Leave at RT O/N 
8ml 0.2M Tris (pH8.5) 
Incubate at50oC for 1hr 
Store in 2ml aliquots at -20oC 
















5ml 1X PBS 
Vortex mixture and incubate at 37oC for 30min 
Filter-sterilise 
Store in dark at 4oC 
Use within one month 
 
Solubilisation Solution (500ml) 
50g SDS 
153ml HCl 





























Appendix C – DNA and Protein Markers 
 
 
Figure 31: DNA molecular weight marker: O’GeneRuler DNA Ladder Mix (Thermo Scientific) used to determine the size of 
qRT-PCR products. 
 
Figure 32: Protein molecular weight marker: Spectra Multicolour Broad Range Protein Ladder used to determine size of 
proteins subjected to polyacrylamide gel electrophoresis and western blot analysis. 
